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Abstract 
Background  
Until recently evidence that BCG protection lasted beyond 10 years was limited.  In the last 
few years, studies in Brazil and in USA (Native Americans) suggested that BCG protection 
against tuberculosis in childhood can last for several decades. The UK’s  universal school-
age BCG vaccination programme was stopped in 2005, and the programme of selective 
vaccination of high-risk (usually ethnic minority) infants was enhanced.  
 
Objectives 
To assess the duration of protection from infant and school-aged BCG vaccination against 
TB in the UK.  
 
Methods 
Two case-control studies of the duration of protection of BCG vaccination were conducted: 
the first on minority ethnic groups who were eligible for infant BCG vaccination 0-19 years 
earlier and the second on white subjects eligible for school-aged BCG 10 to 29 years earlier. 
TB cases were selected from notifications to the UK national Enhanced Tuberculosis 
Surveillance System (ETS) from 2003 to 2012.  Population based controls frequency 
matched for age were recruited .  BCG vaccination status was established from BCG 
records, scar reading, and BCG history. Information on potential confounders was collected 
in computer-assisted interviews. Vaccine effectiveness was estimated as a function of time 
since vaccination, using a case-cohort analysis based on Cox regression.   
 
Results 
In the infant BCG study, vaccination status used vaccination records, as recall was poor and 
concordance between records and scar reading limited.  A protective effect was seen up to 
10 years following infant vaccination (under 5 years after vaccination VE 66% (95%CI 17% 
to 86%); 5 to 10 years VE 75%, (95%CI 43 to 89%)) but weak evidence of an effect 10-15 
years after vaccination (VE 36%, (95%CI negative to 77%, p=0.396)).  The analyses of the 
protective effect of infant BCG vaccination were adjusted for confounders, including birth 
cohort and ethnicity.    
After school-aged BCG vaccination, a 48% protection (95% CI 17 to 68%) was found 10 to 
15 years after vaccination, and 55% (95% CI 30 to 71%) 15 to 20 years after vaccination, 
beyond which time protection appeared to wane. Ascertainment of vaccination status was 
based on self-reported history and scar reading.   
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Conclusions 
 Infant BCG vaccination protection in a population at high risk for TB was shown to last for 
at least 10 years and in the white population school-age vaccination protection lasts for at 
least 20 years.  
The evidence may inform TB vaccine programmes (e.g. timing of administration of improved 
tuberculosis vaccines, if they become available) and cost effectiveness studies.   
 
Limitations  
The difficulty in examining vaccination sites in older females in the high-risk ethnic-minority 
study population and the sparsity of vaccine record data in the later periods precluded 
robust assessment of protection from BCG more than 10 years after vaccination. 
Future work,  
Methods to deal with missing record data in the infant study could be explored including use 
of scar reading.   
Funding details 
NIHR funding project number 08/17/01 
During the conduct of the study JS, IA and LR received other funding from NIHR; IA and LR 
have also received funding from the MRC. PM received funding from the BBSRC. 
Word count: current 500; max 500   
Scientific summary 
Background 
Until recently there was no evidence that protection against TB by BCG lasted more than 10 
years. In the last few years, studies in Brazil and in US (Native Americans) have suggested 
that BCG protection against tuberculosis can last for several decades in some populations.  
These findings were interesting and we conducted this research to add to this body of 
evidence and to determine its relevance to the UK. 
    
Establishing the duration of protection from BCG vaccination against TB is of relevance 
given the higher disease risks in young adults and the increase with age in the proportion of 
tuberculosis cases that are pulmonary, the main source of onward transmission.  We carried 
out two case-control studies of the duration of protection of BCG vaccination: one of infant 
BCG vaccination and one of school-aged BCG vaccination .  The studies took advantage of 
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the UK’s long standing universal school-aged BCG vaccination programme, and the changes 
in 2005, when school-aged vaccination was discontinued and the programme of selective 
vaccination of high risk (usually ethnic minority) infants was enhanced.  
 
Methods 
We carried out two case-control studies in England of cases of tuberculosis and population-
based controls, frequency-matched for age. One involved those in minority ethnic groups 
who were eligible for infant BCG vaccination 1-19 years earlier.  The other involved those 
who were UK born and white who were eligible for school-aged BCG 10 to 29 years earlier. 
TB cases included in both studies were drawn from among those notified in the years 2003 
to 2012 to the UK national Enhanced Tuberculosis Surveillance System (ETS).  Controls 
were recruited from the community in the areas where sampled cases had arisen.  BCG 
vaccination status was established based on BCG records when available, scar reading 
(inspection of both arms), and BCG history (recall of vaccination). Information on potential 
confounders (including demographic and social variables) was collected from cases and 
controls in face-to-face computer-assisted interviews. We studied vaccine effectiveness as a 
function of time since vaccination, using a case-cohort analysis based on Cox regression.   
 
Results 
In the study of infant BCG, vaccination status was based on available vaccination records, 
as there was poor concordance between vaccination records and either a history of BCG 
vaccination or scar reading.  For infant vaccination, in the subset with vaccine records, a 
protective effect was seen up to 10 years following vaccination (under 5 years since 
vaccination VE 66% [95%CI 12% to 85%]; 5 to 10 years VE 76%, [95%CI 44 to 89%] but 
with weak evidence of an effect 10-15 years after vaccination (VE 36%, (95% CI negative 
to 76%, p=0.361)).  The analyses of the protective effect of infant BCG vaccination were 
adjusted for several confounding variables, including birth cohort and ethnicity.  Adjusting 
only for ethnicity, sex and birth cohort, for which there were less missing data (on 
covariates), gave weak evidence of effectiveness (VE 50% (95% CI negative to 78%, 
p=0.096)) 10 to 15 years after vaccination. The high infant BCG vaccine uptake in this high-
risk ethnic minority study population and the sparsity of vaccine record data in the later 
periods precluded further assessment. These results may be modified when methods to deal 
with missing data are further explored.  
After school-aged BCG vaccination a protective effect of 51% (95% CI 21 to 69%) was 
found 10 to 15 years after vaccination, and 57% (95% CI 33 to 72%) 15 to 20 years after 
vaccination, beyond which time protection appeared to wane. Ascertainment of vaccination 
status was based on self-reported history and scar reading.   
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Conclusions 
 Although the findings for infant BCG vaccination in a population at high risk for TB are 
insufficient to conclude that the protection extends beyond 10 years, the evidence is 
stronger for a moderate protective effect up to for 20 years after school-aged BCG 
vaccination in the native white population.  The findings are consistent with the limited 
literature available.   
This new evidence may be useful for decisions on TB vaccine programmes (e.g. timing of 
administration of improved tuberculosis vaccines, if they become available) and for cost 
effectiveness studies.    
Word count: 670 
Plain English summary  
It was believed that the protection given by BCG vaccination against tuberculosis lasted only 
ten years. This was used to define policy in the UK. Recently there were some studies 
suggesting that it could last longer. We studied how the protection changes with time since 
vaccination in two situations – when BCG was given to infants at higher risk of tuberculosis, 
the current policy,  and also when given at school-age (UK policy until 2005). We found 
protection from infant BCG vaccination lasted for 10 years,   but robust data could not be 
obtained to establish vaccination status in some subjects. For vaccine given at school-age, 
we found that protection was substantial for at least 20 years after vaccination (51% from 
10 to 15 years after vaccination, and 57% from 15 to 20 years after vaccination).   
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Background 
Tuberculosis epidemiology  
Tuberculosis (TB) remains a significant and preventable cause of morbidity and mortality 
globally. Approximately 10% of infections with Mycobacterium tuberculosis progress to 
clinical disease.1  The WHO estimates over two billion of the world’s population is infected. 
In 2014, 9.6 million people developed symptoms of TB disease and 1.5 million died from it.2  
In the UK, after many decades during which both the risk of infection with M. tuberculosis 
and the incidence of TB decreased, the last decade of the 20th century and the first decade 
of the 21st century saw a steady rise.3 From 2005 to 2011, numbers remained stable at 
around 8000 cases per year in England. It then declined reaching 6520 in 2014, but 
England still has the highest rates in Western Europe.4 There has been no decline in TB 
rates amongst the UK born population overall; the incidence of childhood TB, including 
miliary disease and meningitis, in UK born children has however started to fall. TB continues 
to be concentrated in urban areas with much higher rates in the most deprived areas and in 
non-UK born populations.5 Drug resistant TB had increased among culture confirmed cases 
in the UK (the percentage resistant to any first line drug increased from 5.6% in 1998 to 
7.5% in 2005), mainly due to a rise in isoniazid resistance6 and has remained stable5. 
However, the percentage with multidrug resistance (MDR) has started to fall and is under 
1.4%, although complex long-term treatment requirements and poor completion rates 
make such outcomes an ongoing concern.  
 
BCG vaccine effectiveness and UK policies on BCG vaccination in relation to the changing 
epidemiology in the UK. 
BCG vaccination is widely used and globally over 100 million doses are given annually. In 
the UK, the vaccine has mainly been given either to infants or to adolescents at school. The 
protection against pulmonary tuberculosis in the UK is  high, when BCG is given to 
tuberculin negative school children at around age 13 years. This was shown by a trial 
initiated by the MRC in 19517 and in subsequent analyses of the effectiveness of the vaccine 
given in the routine school immunisation programme.8 However, there have been variable 
findings with respect to the effectiveness against pulmonary disease of the vaccine in 
different countries or between different studies in the same country.7, 9 , 10  The effectiveness 
of BCG given in infancy (to prevent pulmonary tuberculosis, miliary tuberculosis and 
tuberculous meningitis) has been found to be consistently high in all countries where it has 
been measured.11, 12  Although WHO recommends not to re-vaccinate, mostly because of 
lack of evidence of the efficacy of revaccination, many countries implement re-vaccination 
programmes. Trials in Malawi and more recently in Brazil found none to a modest increase 
in effectiveness associated with repeat BCG vaccination.13, 14 
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Although the MRC trial of adolescent vaccination with BCG demonstrated high protection in 
the UK,  there have been several subsequent policy changes with respect to BCG 
vaccination in the UK, prompted by changes in the epidemiology of TB. In brief, from 1953 
BCG vaccine was given to tuberculin negative (“PPD negative”) school children at age 10-13 
years, as part of the national vaccination programme. In 1972, as the proportion of cases of 
TB in ethnic minorities increased, BCG vaccination in infancy was recommended for new-
borns of recent immigrants from countries with a high incidence of TB (e.g. Indian sub-
continent and Africa) as well as all refugees and-asylum seekers. It was also given to all 
new-borns in some areas (Health Districts/ Primary Care Trusts (PCTs)) with high TB 
incidence.  
In 1991, a survey was conducted in the UK on how well the policies for BCG vaccination in 
the first year of life were implemented. At that time, five districts offered BCG to all new 
born children; 31 to none; and 148 to infants born to those in ethnic groups from the Indian 
subcontinent, Africa, West Indies, China, Middle East and Southeast Asia. Of the 184 
districts, 120 reported that they offered vaccine to the new-born children of recent migrants 
from other countries with high incidence of tuberculosis.15   
There was discussion on whether BCG vaccination in the general population should be 
discontinued when the risk of TB decreased based primarily on the high number of 
vaccinations needed to prevent one case of tuberculosis, in the UK and worldwide.16 The 
International Union against Tuberculosis and Lung Disease (IUATLD) developed a set of 
criteria for the discontinuation of mass BCG programmes in low prevalence populations.17 
The IUATLD recommends BCG be discontinued if: 
An efficient TB notification system is in place and  
 The average annual notification rate of smear positive pulmonary tuberculosis is less 
than 5 per 100,000, or 
 The average annual notification rate of tuberculous meningitis in children under five 
years of age has been less than 1 per 10 million population over the previous five 
years, or 
 The average annual risk of infection is less than 0.1 percent. 
 
The UK met all these criteria and BCG vaccination policy for the UK was changed by the 
Department of Health in 2005 to the current policy.18  The school vaccination programme 
was stopped, and BCG vaccination was recommended to infants on a risk-based approach, 
in line with the IUATLD guidelines. In the UK infants are eligible for vaccination if they have 
a parent/grandparents originating from a high TB incidence country and any infant is also 
eligible if born in a part of the UK with a high incidence of tuberculosis (>40 per 100,000). 
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Some occupational groups, and uninfected contacts of TB cases, are also recommended to 
receive BCG vaccination.19   
 
Evidence for the duration of BCG protection  
In the UK, the efficacy of BCG by time since vaccination of adolescents at school was 
estimated in the MRC trial as follows: 84% during the first five years after vaccination, 68% 
between 5 and 10 years since vaccination and 63% between 10 to 15 years.7 Although all 
these estimates were statistically significantly different from zero, the number of cases 10 
to 15 years post-vaccination was small, and there was a wide 95% confidence interval on 
the efficacy estimate (17% to 84%). There were too few cases between 15 and 20 years 
after vaccination to assess efficacy. Protection by time since vaccination, with 95%CIs 
(calculated by us based on the trial data presented in the paper) is given in table 1. The 
level of protective effect in the first ten years after vaccination was confirmed in a 
subsequent cohort analysis of data from the school-aged BCG vaccination programme in 
England.8 There are no data regarding long-term protection post-infant BCG in high-risk 
groups.  
 
Table 1:  Numbers of cases of TB at different intervals since BCG vaccination in vaccinated 
and unvaccinated groups in the MRC trial among 13-year old schoolchildren. 
Trial group No. of 
participants 
Time since vaccination (years) 
0-5 5-10 10-15 15-20 
Negative reaction to 
tuberculin unvaccinated 
12867 160 67 16 5 
Negative reaction to 
tuberculin BCG vaccinated  
13598 27 22 7 6 
Negative reaction to 
tuberculin vole bacillus 
vaccinated 
5817 12 11 2 1 
Total negative vaccinated 
with either vaccine 
19415 39 33 9 7 
BCG Vaccine effectiveness (95% CI)  84%  
(77-
89) 
68%  
(51-79) 
63%  
(17-84) 
9%  
(-187 to 71) 
 
The HTA stated, and we agree, that it is not known how long BCG protection lasts, 
particularly in different age and population groups, and this hinders the development of 
evidence-based policies. Until recently there was little evidence of protection lasting beyond 
ten years after vaccination at any age. In a review of published studies conducted by two of 
the current authors, the pooled estimate of protection after 10 years was 14% (95% CI –
9% to 32%).20 Considerable heterogeneity was observed between studies in the annual 
change in BCG vaccine efficacy with time since vaccination. There was no relation between 
average annual change in efficacy and overall efficacy. As with most vaccines, 
immunological memory may wane with time, leading to a lower level of protection. Other 
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explanations proposed include decreasing susceptibility among the unvaccinated because of 
continued exposure to environmental mycobacteria or an increase in the proportion of 
disease caused by reactivation or re-infection, against which BCG may not protect.21 
An update of this systematic review of the duration of protection conferred by BCG against 
TB has been conducted by our group (HTA Project: 08/16/01 - Systematic Review and 
Meta-Analysis of the Current Evidence on the Duration of BCG Protection).22  It included, as 
well as a systematic search for any other studies, the recent additional follow-up of a BCG 
vaccine trial in Native Americans (who were on average 7 years of age when vaccinated) in 
the 1930s, which has reported protection lasting for several decades,23 as well as a cohort 
study in the control arm of the Brazilian BCG re-vaccination trial suggesting protection 
lasted 15 to 20 years.24   
There is, however, evidence from some countries of poor protection by BCG in adult life, 
and much of the existing research is of uncertain relevance to the UK.  The aims of this 
research project were to estimate the duration of protection of BCG given to high-risk 
infants in the UK and separately to school-aged children in the general population. If the 
study provides evidence of long duration of BCG protection, beyond 10 years, this will have 
several implications. They include changes to estimates of the cost-effectiveness of BCG, 
the number of vaccinations needed to prevent a case, the possible characteristics of new 
BCG-like vaccines and the timing of vaccination for any new tuberculosis vaccine developed 
i.e. provide the necessary evidence for vaccination policies as well as inform research and 
development of new TB vaccines.  
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Research Objectives: 
Estimate the change in the effectiveness of BCG with time since vaccination in preventing 
tuberculosis in today’s UK population.  
Primary objectives:  
1. To estimate the effectiveness of BCG vaccination when given in the first year of life 
(“infant BCG”) to high risk groups in preventing tuberculosis in five-year intervals since 
vaccination in the infant programme.   
2. To estimate the effectiveness of BCG vac cination when given in adolescence 
(“school-aged BCG”) to the general population for preventing tuberculosis in five-year 
intervals since vaccination starting at 10 years since vaccination.  
3. To explore whether protection wanes with time since vaccination, in high-risk groups 
and in the general population.  
 
Health technologies assessed:  
BCG vaccination in the UK as given either  
1. To infants at higher risk of TB (referred to in this report as infant BCG) 
2. To schoolchildren in the general population (referred to in this report as school-aged 
BCG) 
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Methods 
Overview    
Two main observational analytic studies aiming to estimate the effectiveness of BCG vaccine 
against TB by time since vaccination were conducted; we also conducted three supporting 
studies. The two main studies were case control studies aimed at (1) estimating the 
effectiveness of BCG given to infants in high risk groups (results generalizable to high risk 
groups in the UK), and (2) estimating the effectiveness of BCG given in school-age to the 
general population (results generalizable to the UK population). The three supporting 
studies were (1) a survey of BCG vaccination policy in England, (2) A pilot study for the 
main observational studies, and (3) a validation study of the BCG scar reading.  
In the two case-control studies, TB cases included in the study were sampled among those 
notified in the years 2003 to 2012 to the UK national Enhanced Tuberculosis Surveillance 
System (ETS). Controls were recruited from the community in the areas where sampled 
cases had arisen.  BCG vaccination status was established based on BCG records when 
available, scar reading (inspection of both arms), and BCG history (recall of vaccination). 
Information on potential confounding variables (including demographic and social variables) 
was collected from cases and controls in a face-to-face computer-assisted interview 
conducted by trained staff from the National Centre for Social Research (NatCen), a leading 
centre for independent social research with over 40 years’ experience in nation-wide 
surveys. Clinical and microbiological information, including type of disease for cases was 
retrieved from the ETS. 
 
Ethics  
The protocol for all studies, information leaflets and data collection tools were reviewed and 
approved by the NHS National Research Ethics Service (NRES) Committee – London and 
South East (REC Reference 11/H1102/11) and LSHTM Observational / Interventional 
Research Ethics Committee (LSHTM Ethics reference 5996). NHS (R&D) permission was 
obtained with Public Health England (formerly the Health Protect ion Agency) as the “NHS 
participating organisation”. 
 
We report first on the policy survey (one of the supporting studies), then on the two main 
observational studies.  
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SURVEY OF INFANT-BCG VACCINATION POLICIES IN ENGLAND 
 
Background 
There appeared to be widespread variation at the local level, in the implementation of the 
recommendations for infant BCG vaccinations, as well as vaccine delivery pathways.  
A survey of both past and current vaccination policies was conducted to support the main 
studies by assessing what infant-BCG provision was in place prior to 2005 in local areas; 
and to identify and engage with services or individuals on the delivery pathway who 
managed or had access to vaccination records.  
 
Methods  
We designed a standardised, mostly close-ended structured questionnaire, covering both 
the historical and current BCG vaccination policy in and outside infancy, eligibility criteria 
and their documentation, delivery pathways and constraints to service delivery. The 
questionnaire was tested by asking Immunisation Coordinators from four London Primary 
Care Trusts (PCT) to complete them and they were then adjusted accordingly. 
We carried out a questionnaire-based survey of all 152 PCTs - the then local administrative 
areas for health care services in England between November 2010 and March 2011. We also 
checked PCT websites and related NHS sources for publically available documents to assess 
agreement with the questionnaire data received. Details of the survey are published as a 
peer-reviewed paper.25  
We also obtained the source data (original questionnaires / tables) from previous BCG policy 
surveys from the investigators in order to complement information on historical infant 
vaccination policies. 
 
Results 
Questionnaires were returned from 85% (129/152) of the PCTs in England. There were no 
differences in TB notification rates between responding and non-responding PCTs. We found 
publically available current BCG policy documents for 114 (88%) of the 129 PCTs from 
which responses were obtained. Two (2%) PCTs were excluded from subsequent analysis 
because their BCG polic ies could not be determined clearly from their responses.  
Current BCG vaccination policy 
The agreement with publically available BCG policy documents was high, with only three 
(2%) PCTs reporting polic ies that were different from the information in these documents. 
Details of the findings are given elsewhere.25 In summary, the new policy for the delivery of 
infant BCG in high risk groups had been implemented in all PCTs but with considerable 
heterogeneity in the organization of the delivery of the vaccine and some difficulties in the 
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identification of eligible children. Sixteen (13%) of the 127 PCTs reported universal infant 
vaccination and 111 (87%) selective infant vaccination. PCTs with selective infant policy 
most frequently vaccinated on postnatal wards (51/102, 50%) whereas PCTs with universal 
infant vaccination most frequently vaccinated in community clinics (9/13, 69%; p=0.011).  
All (100%) PCTs that vaccinated primarily on postnatal wards did so during the infants’ first 
month of life whereas only 13/37 (35%) PCTs that mainly vaccinated in community clinics 
did so in the infants’ first month of life (p<0.001). 
 
Past (pre-2005) BCG vaccination policy 
Prior to 2005, the national policy was to vaccinate all TST-negative schoolchildren aged 11 
to 14 years. The tuberculin test was performed by school nurses, who also administered the 
vaccine in eligible children. However, the 1983 survey of BCG vaccination policies reported 
that five health authorities had stopped their routine BCG vaccination programme for 
schoolchildren (two in 1974 and one each in 1977, 1980 and 1983), and replaced it with 
selective infant-BCG vaccination targeting immigrants.26, 27 By 1992, at least 15 health 
authorities in England and Wales had stopped their routine schoolchildren BCG vaccination 
programme, mostly in areas with very low TB notification rates.15 The later survey also 
found that 18 health authorities offered BCG to selected groups at school entry, mostly 
recent immigrants, although this was offered in only 2 of the 15 districts that discontinued 
BCG for schoolchildren.15 
Infant-BCG vaccination pre-2005 
The survey of BCG policies in 1983 found that six of the 201 health districts in England and 
Wales had universal infant-BCG program, while a further 98 health districts already had 
some form of selective infant-BCG vaccination programme, mostly targeting immigrants’ 
new-borns and/or neonatal TB contacts.26, 27 The 1992 survey reported that out of the 184 
health districts surveyed, five had universal infant-BCG vaccination, and 148 had a selective 
infant-BCG vaccination programme (including 14 of the 15 districts where schoolchildren 
vaccination was discontinued).15 The main groups targeted in areas with selective policies 
were infants from ethnic minorities (all 148 districts) and recent immigrants from high TB 
burden countries (120 districts), as well as infants from families with history of TB (40 
districts). This survey also found that only one of the 31 health districts with no infant -BCG 
programme had an estimated population of Indian sub-continent origin greater than 10%. 
Overall, previous surveys suggest that about half of health districts in England and Wales 
already offered BCG to ethnic minority infants by 1983, with over 80% doing so by 1992, 
including nearly all areas with an estimated population from the Indian subcontinent origin 
of more than 10%. 
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BCG administration 
In 1983, 152/201 (76%) health districts vaccinated using a syringe and needle exclusively, 
whereas 14 used a jet injector, and 25 used either of these methods at the discretion of the 
provider. Two districts used the multi-puncture method.27 By 1992, 163/169 (96%) health 
district still implemented routine schoolchildren vaccination using a needle and syringe, with 
three using multiple-puncture and one using a jet injector. All districts offering infant -BCG 
administered it using a syringe and needle.15  
 
Discussion 
The data for this survey were collected during and in the aftermath of a major 
reorganisation of the National Health Service (NHS). This complicated access to key 
informants as staff and responsibilities were not clear or certain, and also implies that 
potential implications of the recent NHS reorganisation for BCG vaccination policies at the 
local level are not now reflected in this document. 
Implication of findings for the main studies 
One of the main features of BCG vaccination policies in England highlighted by this and 
previous surveys is the substantial heterogeneity in infant -BCG policies between health 
areas, as well as the changes over time. However, the constant patterns relevant to the 
main studies are that: 
1. Up to 1992, over 90% of health districts still had a routine universal schoolchildren 
vaccination programme. Given that the birth cohorts eligible for the main study of 
BCG in the general population are subjects born in 1965-1989, it is reasonable to 
assume that most of the target population had similar opportunities/exposure to the 
schoolchildren vaccination programme. 
2. From 1983, more than 50% of health districts had an infant-BCG program with ethnic 
minorities in its prime population target, increasing to over 80% by 1992. 
Furthermore, all but one districts with >10% residents with Indian subcontinent 
origin (the majority minority ethnic group in England and Wales) had an infant -BCG 
program. 
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OBSERVATIONAL STUDIES OF BCG EFFECTIVENESS WITH TIME SINCE 
VACCINATION IN ENGLAND 
Objectives: 
The primary objectives of these two studies were respectively: 
1. To estimate the effectiveness of BCG vaccination when given in the first year of life 
(“infant BCG”) to high risk groups in preventing tuberculosis in five-year intervals 
since vaccination after infancy.   
2. To estimate the effectiveness of BCG vaccination when given at school-age (“school-
age BCG”) to the general population for preventing tuberculosis in five-year intervals 
since vaccination starting 10 years after vaccination.  
For both exposures, to explore whether protection wanes with time since vaccination.  
 
Methods 
Study design and study areas: 
Participants to both studies were recruited using a case-control design. For logistical 
efficiency, the recruitment for the infant BCG study was restricted to areas of England with 
30% or greater resident Black and Asian Minority Ethnic (BAME), based on the 2001 general 
census. These communities are geographically clustered. The school-age BCG study was 
across England, reflecting the much larger geographical spread of TB cases in the target 
population. A pilot study to test methods for recruiting controls was first conducted.  
Pilot study 
The main objectives for the pilot study were: 
1. To estimate the response rate for cases in order to refine the sampling strategy 
2. To assess the feasibility of the control recruitment strategy (nominated controls) 
3. To field-test the operating procedures and the questionnaire 
A total of 115 subjects with previous TB diagnosis notified to the ETS were selected and 
invited to take part, 58 for the infant BCG study and 57 for the school-age BCG study. 
Those successfully recruited were invited to nominate up to five non-relative acquaintances 
of roughly similar age, gender and broad ethnic background residing in the fieldwork area, 
to serve as ‘controls’ 
 
Study main exposure and primary outcome 
Infant BCG study:  
Main exposure: BCG vaccination given in infancy to subjects at higher risk of TB disease 
(study population restricted to BAME populations as they were the main target of 
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vaccination programme), as recommended by UK Department of Health guidelines (Green 
Book).19 
Primary outcome: Level and duration of BCG-derived protection against any notified 
tuberculosis disease up to 19 years after vaccination.  
School-age BCB study:  
Main exposure: BCG vaccination given to tuberculin skin test (TST) negative 
schoolchildren as part of the UK universal school BCG vaccination programme until 2005 
when it was discontinued.  
Primary outcome: Duration and level of BCG-derived protection against any notified 
tuberculosis disease from 10 to 29 years after school-age vaccination 
 
Participants 
Infant BCG study:  
Cases were UK-born subjects from BAME background with a confirmed first TB episode 
diagnosed and notified to Public Health England (PHE, formally Health protection Agency 
HPA) Enhanced Tuberculosis Surveillance System (ETS) between 2003 and 2012, aged 
between 1 and 19 years at the time of diagnosis (i.e. born between 1984 and 2012), and 
residing in the study area at the time of diagnosis. The BAME backgrounds included those 
from high TB burden settings. They were any Black or South Asians (including from India, 
Pakistan, Bangladesh, Nepal, Bhutan, Maldives, Sri Lanka, including those whose families 
were originally from these backgrounds but who migrated to Britain from other regions, for 
example the Caribbean, east or southern Africa).  
Controls were population based UK-born subjects from the same target BAME 
backgrounds, residing in the same study area as cases, from the same birth cohorts as 
cases (i.e. born between 1984 and 2012), and with no previous episode of TB. Controls 
were frequency matched to cases within 5 year birth cohorts. 
Exclusion criteria: Cases with known HIV infection were not included in the study. This 
criterion was not applied to controls because the prevalence of HIV infection in the general 
population from which they are sampled was small. Cases and controls from BAME 
backgrounds other than those targeted (e.g. Chinese, Japanese, Korean, etc.) were not 
included. 
 
School-age BCG study:  
Cases were UK-born subjects from White ethnic background with a confirmed first TB 
episode diagnosed and notified to Public Health England (PHE, formally Health protection 
Agency HPA) Enhanced Tuberculosis Surveillance System (ETS) residing in England at the 
time of diagnosis between 2003 and 2012 and aged between 23 and 38 years at the time of 
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diagnosis (i.e. born between 1965 and 1989). School-age BCG was routinely offered to 
schoolchildren aged about 13 years (range 10-15 years), so the age range of cases would 
allow measurement of the effect of the vaccine between about 10 to 29 years after 
vaccination.   
Controls were UK-born subjects from White ethnic background residing in England, from 
the same birth cohorts as cases (i.e. born between 1965 and 1989), and with no previous 
episode of TB. Controls were frequency matched to cases on 5-year birth cohort. 
Exclusion criteria: Cases with known HIV infection were not included. This criterion was 
not applied to controls because the prevalence of HIV infection in the general population 
from which they are sampled was small.  
 
Sample size:  
The sample size calculations for both studies was based on assumptions on expected BCG 
vaccine uptake, and minimum level of Vaccine Effectiveness (VE) for successive time band 
since vaccination for the different populations. All calculations were for a frequency-matched 
case-control study design, with 90% power and 5% signific ance level. Numbers were 
inflated by 15% to allow for post-recruitment exclusions due to ineligibility and loss of 
power after controlling for confounding variables. For the infant BCG study, at a ratio of 
case to control of 1:1, we estimated the required sample to be 627 cases and 627 controls. 
For the school-age BCG study, the number of eligible cases available to be invited was 
limited, hence the sample size was estimated for an average ratio of up to 2 controls per 
case, for a total of 665 cases and 1183 controls. A ratio of up to 2 controls per case in the 
school-age BCG study was applied to mitigate the effect on  statistical efficiency in, of an 
expected low case recruitment rate based on the results of the pilot study; however, the 
intention was to recruit as many cases as possible. The detailed sample size estimates for 
each study are presented in tables 2 and 3. 
 
Table 2 Sample size estimates for the infant BCG study 
Age at TB 
diagnosis 
time since 
vaccination 
Assumed 
BCG uptake 
Min VE to 
be 
detected 
Frequency-matched 
design with ratio of 1 
control per 1 case 
        Case Control 
0 to 5 yrs 0 to 5 yrs 90% 60% 252 252 
6 to 12 yrs 6 to 12 yrs 80% 60% 158 158 
13 to 17 yrs 13 to 17 yrs 60% 50% 217 217 
Total number in 'infant-BCG sample' 627 627 
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Table 3 Sample size estimates for the school-age BCG study 
Age at TB 
diagnosis 
time since 
vaccination 
Assumed 
BCG uptake 
Min VE 
to 
detect 
Frequency-matched design 
with ratio of 2 controls per 1 
case 
        Case Control 
23 to 27 yrs 10 to 14 yrs 80% 60% 116 (145) 232 (258) 
28 to 32 yrs 15 to 19 yrs 80% 50% 208 (260) 416 (463) 
33 to 37 yrs 20 to 24 yrs 80% 50% 208 (260) 416 (463) 
Total number in 'schoolchildren-BCG sample' 532 (665) 
1064 
(1183) 
It was possible that about 10% controls and 20% cases would not be eligible (discarded) because 
tuberculin positive (PPD +), hence number in brackets were the actual recruitment target taking this 
into account           
  
Study sampling: 
Cases selection: For both studies, eligible TB cases were identified from the ETS database 
based on the date of diagnosis and reported date of birth, residential address at the time of 
diagnosis and self-reported ethnic background. Cases with a reported previous TB episode, 
or with a previous notification of TB in the database were not included. For the infant study, 
cases were included if they resided in the study area (defined to include small areas where 
30% or more of the population were BAME). For the school-aged study the study area 
included all of England.   
Controls selection: This was amended after the pilot. We required community-based 
controls, who represented the population in which the cases occurred. We had two potential 
strategies for this: the first, which was lower cost but high risk, was nominated controls. We 
piloted this strategy to recruit individually matched controls among non-relative 
acquaintances nominated by cases. The pilot study indicated that nominated controls were 
not feasible: people were either reluctant to nominate friends or reported that they did not 
have friends of eligible age or ethnicity. The control recruitment strategy was thus changed 
to our second choice strategy (more resource intensive but lower risk): a self-weighted 
multi-stage stratified sample of the target populations across the area from which cases 
were recruited. A multi-stage sampling was preferred to a straightforward simple random 
sampling in order to ensure wider geographical coverage of respective study areas, while 
maintaining reasonable clustering of field data collection for optimal logistical efficiency: 
For the infant BCG study, we used a two-stage self-weighted sampling design:  
Based on previous work by the Health Survey for England28, 29 and the 2001 census,30 we 
estimated screening on average 12 residential addresses would provide one eligible (based 
on BAME and birth cohort) control successfully recruited from the community. A total of 
7750 addresses were selected probability proportional to size (PPS) of the eligible BAME 
population in the study area: geographical areas with 30% or more BAME residents based 
on the 2001 census. Inter-census estimates were not thought to be as robust and not 
available by small areas.  
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The first stage consisted of sampling the Lower level Super-Output Areas (LSOAs) with 30% 
or more resident BAME population by PPS. LSOAs are designed to have a fairly socially 
homogeneous population of an average 1500 residents each.31 A total of 2,659/32,482 
(8.2%) LSOAs had 30% or more BAME residents, account ing for 50% 
(2,027,398/4,024,287) of the total BAME population in England. The study area also 
included 60% of all eligible TB cases in these groups notified to the ETS.  
The second stage was a simple random sampling (SRS) of seven (7) residential addresses 
within each LSOA selected in the first stage. This was done using the Small-user Postal 
Address File. To ensure equal geographical spread of selected addresses within the LSOA, 
we randomly sampled seven distinct postcode units in each LSOA, then one address per 
postcode unit. Postcode units each have on average 15 residential addresses, and LSOAs 
count on average 30 postcode units each. 
Overall, 1107 LSOAs were sampled with PPS out of 2659 with ≥30% BAME residents, and in 
each selected LSOA, 7 residential addresses were selected using SRS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Summary of sampling strategy for the infant BCG study 
 
For the school-age BCG study, we used a three-stage self-weighted sampling design to 
reflect the much wider study area (whole of England): 
England = 32482 LSOAs  
TB cases  in restricted s tudy area  
Cases in restricted area  noti fied to 
the ETS (>85% reporting) 
)completeness ) 
 627 Cases  to enrol  
 1107 LSOA sampled with PPS ethnic 
minority resident population  
7 addresses/LSOAs  (tota l  7750) sampled 
us ing SRS of postcodes   
627 controls  to recrui t 
 (~ 1/12 addresses  productive)  
Frequency matched to cases on year of birth 
and sex 
Study Area = LSOA >=30% Ethnic minori ty 
2659 LSOAs  (with 50% of BAME population in England) 
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We estimated that a total of about 9500 residential addresses would have to be screened to 
meet our target, based on an average of one eligible control successfully recruited from 
every 7-8 addresses screened based again on the HSE and census data broken down by age 
and ethnicity. 
The first stage was the selection of 449 Mid-level Super-Output areas (MSOA) out of a total 
of 6781 in England, with probability proportional to the size (PPS) of their 2010 mid-year 
estimates of population aged 25-49 years.32 MSOAs consist of contiguous LSOAs, 
constrained by the 2003 local authority boundaries; each has a minimum population of 
5,000, average 7,200 inhabitants.31 
The second stage was the random selection of three LSOAs in each MSOA, by PPS; 
The third stage was the selection of seven residential addresses from each LSOA by SRS 
using the same procedure as for the infant-BCG study above. 
In total, we selected 449/6781 MSOAs, and a total of 1347 LSOAs across England (3 per 
MSOA). Seven randomly sampled addresses were screened in each LSOA, for a total of 
9423 addresses screened for eligible controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Summary of sampling strategy for the school-age BCG study 
 
Data sources:  
Data for the studies were obtained from four main sources:  
Study Area = England 
6781 MSOAs  = 32482 LSOAs  
Al l  El igible TB cases  in England  
449 MSOAs  sampled PPS 25-49 years  old res ident 
population aged 
Cases  noti fied to the ETS (>85% reporting 
completeness ) 
 >= 665 Cases  to enrol   
3 LSOAs/MSOA (tota l  1347) sampled PPS 
res ident 25-49 years  old population  
7 addresses/LSOAs (total 9423) sampled SRS 
of postcodes   
1183 controls  to recrui t  
(~1/7-8 addresses  productive)  
Frequency matched to cases  on year of bi rth 
and sex 
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Face to Face interviews: the core study data, including indicators of BCG status (vaccination 
history, inspection of both arms for vaccination scar, and personally held vaccination record 
or card e.g. the Red book) were collected in the community through Computer-assisted 
Personal Interviews (CAPI) by trained and experienced field interviewers. This data source 
will be called in this document CAPI data.  
Surveillance register: Clinical information for TB cases was obtained from the Public Health 
England’s (PHE) Enhanced Tuberculosis Surveillance system (ETS). This data source will be 
called in this document ETS data. 
NHS vaccination records: Information on BCG vaccination records held by the NHS was 
requested from, and manually searched for, in the Child Health Information Systems (CHIS) 
of NHS Primary Care Trusts (PCTs) as well as NHS Community Care Trusts in areas in which 
participants have resided at the time when eligible for vaccination. This data source will be 
called in this document NHS records 
Other: Small area-level (LSOA) Indices of Multiple Deprivation (IMD) – a proxy-measure for 
socio-economic status - were obtained from the ONS English Indices of Deprivation 2010,33 
by linkage using study participants’ residential postcodes. Local annual TB rates in the area 
of residence (local authorities 1988-90 and PCTs 2005-2007) when eligible for vaccination 
were obtained from PHE historical data. 
 
Study variables 
Indicators of vaccination status 
Data were collected on four indicators of BCG status, respectively history (recall from parent 
or respondent), the inspection of both arms for BCG scar by the interviewer following a 
standardised procedure, personal vaccination record (Red book) or card, and NHS 
vaccination records. All four indicators were incomplete and had strengths and limitations 
for the two different studies: 
 Vaccination history:  
o For the infant BCG study, the information was collected from parents or 
subjects (if older and living away from home, but they were encouraged to 
check with their parents over the phone). Subjects were, of course, not able 
to remember vaccination in the first year of life, and parents’ report was 
subject to considerable recall bias because BCG vaccination was  confused 
with any of the several other vaccinations given in infancy. 
o For the school-age BCG study, BCG history was less likely to be affected by 
recall error, as BCG was the sole vaccine routinely given at school in all 
children aged around 13 years (at an age when they can recall). 
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 Inspection for BCG scar: Interviewers were trained to recognise a BCG scar and 
inspected both arms for BCG vaccination scars after consent was obtained. Higher 
refusal rates were noted by young/teenager female cases with family origins in Africa 
and Pakistan.  
 Personal vaccination record: Study participants were encouraged to look for any 
vaccination record or card ahead of the interview. The most common personally-held 
vaccination record, (commonly known as the “Red book”), was introduced in England 
in the mid-1990s, thus, these records were missing for older participants to the 
infant BCG study.  No participants to the school-age BCG study had hand held 
records.   
 For the infant study, vaccination was checked through the Child Health 
Information System (CHIS) in local area health trusts. There were several 
practical challenges: the decentralisation of primary health care in the NHS, with 
heterogeneity in how data are stored and procedures to request authorisations 
between trusts; the major NHS reform that coincided with our study period which 
meant that not every care trust could be successfully contacted to check their 
records; the fact that CHIS records are also discarded or archived by regulatory 
requirements when individuals reach an older age, varying from 21 to 25 years 
depending on the area. Any such records need only to be kept to 25 years of age 
before they can be destroyed. 
 For the school-age BCG study, there was no central database of school 
vaccination records, and this information was inconsistently recorded in the CHIS.  
NHS vaccination records were therefore not available for nearly all participants. 
Tuberculosis events:  
Information on date of notification of TB event, as well as reported date when symptoms 
started and date of diagnosis for all cases was retrieved from the ETS. We also extracted 
data on the site of disease, as well as checking that no previous TB episode was reported. 
Controls were asked for any past TB diagnosis, and their details were also checked against 
the ETS for any notified TB. 
Other variables / potential confounders: 
 Basic demographics, including date of birth, sex, and ethnic background (CAPI): 
ethnic background was self-assessed, choosing from the standard ONS categories in 
the latest UK general population census.  
 Education level (CAPI): for the infant BCG study, we collected information on 
education level of both parents, and for the school-age BCG study, we collected 
information on own education level. 
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 Small-area level deprivation index: The postcode of cases at the time of diagnosis as 
well as that of controls was used to obtain the LSOA-level indices of multiple 
deprivation (IMD) scores and ranks, a proxy-measure of socio-economic status. The 
IMD, a composite measure of deprivation generated by the ONS, combines scores in 
7 deprivation domains (income, employment, health and disability, education, skills 
and training, crime, and living environment).33 
 Household crowding (CAPI): information was collected on the number of residents in 
the household, and the number of rooms in general (excluding kitchen and 
bathroom) and the number of bedrooms. This was used to generate two commonly 
used measures of crowding, the number of persons per room (PPR) and the number 
of persons per bedroom (PPB).34, 35 
 Background risk of TB: We collected data on broad world region of origin of parents 
and grandparents, as well as frequent travel and/or prolonged stays (≥3 months) to 
parts of the world with high TB burden. 
 Lifestyle/behaviour risk factors (CAPI): For the school-age BCG study, participants 
were also asked about potential risk behaviours, including history of tobacco 
smoking, alcohol abuse, drug misuse, stays in prison and homelessness. 
 Other: information was collected on areas of residence of participants between birth 
and age 14 years. These data were used to retrieve historical average TB notification 
rates in those areas at relevant time periods as a proxy-measure of the local TB 
epidemiology. 
 
Ethics and consent 
Eligible subjects were given detailed information on the relevant study via an information 
leaflet and a dedicated webpage, with the opportunity to ask clarification questions. For 
those willing to take part in the studies, we obtained up to three separate informed 
consents, respectively for (i)the face to face interview, (ii) the inspection of both arms for 
BCG characteristic scar (and photographs for about 25%), and (iii) permission for us to 
contact the NHS using their personal details to check their vaccination records for BCG. 
Subjects aged less than 16 years old provided an assent, with formal consent obtained from 
their parent or legal guardian.  
All subjects contacted for this study were given the option to opt-out following the initial 
invitation, in which case no further contact was attempted by the field worker. Subjects 
could also freely withdraw from the study at any stage, including during the interview, or 
even afterwards by telephone and their data deleted. 
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Participants to the study were given a £15 gift voucher as compensation for their time, 
irrespective of whether they completed the interview or withdrew their consent at any 
stage. 
 
Field procedures and data collection 
The pilot study for the recruitment of cases and nominated controls was carried-out in 
September and October 2011.  
The main change after the pilot was the approach to control recruitment, described above. 
After preparations for the new approach to control recruitment were complete, the main 
data collection was conducted from February 2012 to September 2014. 
Cases were sent information letters inviting them to take part to the study, and offered the 
opportunity to request further information or opt out either by telephone, or by returning an 
opt-out slip. Controls were sent similar advance information letters with opt-outs as above 
to the residential addresses selected for screening.  
Trained interviewers attempted contact with both the invited cases and selected control 
residential addresses with a standard visit schedule, including week and weekend days, and 
morning, afternoon and evening visits. For controls, the residents at sampled addresses 
were first screened for eligibility. If required at the door, a translation screening card with 
17 of the most common other languages spoken in England was used to ask which language 
was their first language together with a show-card asking for their help with the study in 
their first language. Eligible controls were provided information on the study. Informed 
consent was obtained from all those eligible and willing to participate to the study before 
face-to-face interviews were conducted.  
Study participants aged 16 years and older were directly interviewed. Parents or those with 
parental responsibilities were interviewed for those aged 0 to 15 years. For the infant BCG 
study where some parents from BAME were not fluent in English, translation (from up to 17 
most commonly spoken foreign languages in England) was offered if requested.  
All interviews were carried out by experienced staff from NatCen, a leading independent 
social research non-for profit organisation that routinely conduct other large-scale national 
surveys (e.g. Health Survey for England (HSE), National Survey of Sexual Attitudes and 
Lifestyles (NatSAL) etc.). All interviewers undertook a day’s training specifically for this 
study before taking part in any field work, including prior homework and intensive practical 
training on inspection of both arms to identify BCG vaccination scars. The training of scar 
reading included photos and volunteers with and without scars.  
Monitoring and quality control during field data collection included formal supervisory field 
visits of individual interviewers and blind telephone recall of at least 10% randomly selected 
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study participants, checking for quality of face-to-face interviews, compliance with protocols 
and procedures for interviewing, as well as other specific instructions.   
The CAPI included a standardised pre-tested questionnaire with only close-ended questions, 
and a pre-set standard script that interviewers had to read.  Part of the questionnaire for 
the school BCG study collected sensitive data on lifestyle behaviour on tobacco, alcohol and 
controlled substance use, and previous stay in prison via a Computer-Assisted self-interview 
(or CASI), during which the interviewee entered the data themselves then locked the data 
to be inaccessible to the interviewer before returning the laptop to them.  
Information on a range of other potential confounding variables was collected during the 
interview, including indicators of socio-economic status, education level, household 
crowding, lifestyle behaviours etc.  
 
Analysis 
Data cleaning and descriptive analysis 
For both studies, data from the different data sources were merged, cleaned and checked 
using consistency and range checks. The distribution of quantitative variables was examined 
and they were transformed into categorical variables as required (IMD scores, birth year). 
The distribution of covariates and any missing data on them were summarised by case and 
control status. 
Definition of vaccination status 
Infant BCG study 
After exploration of completeness, agreements between the different indicators of 
vaccination status were assessed. Based on the assessment we judged that BCG status was 
best defined using combinations of observed vaccination records as described in table 4 
below. Briefly, the recording of BCG in either the Red book or NHS record was used as 
evidence of previous BCG vaccination. Subjects were classified as unvaccinated only if  both 
records were available, and there was no BCG recorded in both records.  The date of BCG 
vaccination was taken as that reported in the vaccination records. 
Table 4: Definition of BCG status for the infant BCG study using both vaccination records 
Red Book NHS Record BCG vaccination status 
(definition 1) 
BCG Recorded BCG Recorded 
Vaccinated 
 
BCG Recorded BCG not recorded 
BCG not recorded BCG Recorded 
BCG not recorded  BCG not recorded Not vaccinated 
BCG not recorded Missing 
Treated as missing 
Missing BCG not recorded 
Missing Missing Missing 
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School-age BCG study 
After checking for completeness, BCG vaccination status was based on the two indicators 
available, i.e. self-reported history and scar inspection. Self-reported history was based on 
recall of TST testing prior to vaccination and subsequent BCG vaccination; participants ’ self-
reported BCG history was therefore classified into three categories: 
 Convincing history of BCG vaccination: subjects who recalled the TST testing, and 
subsequent BCG vaccination 48 to 72 hours later, or post-vaccination soreness, 
pustule and/or scar. 
 Probably BCG vaccinated: those who reported receiving BCG at school, but do not 
recall the TST testing and/or the post-vaccination soreness, pustule or scar.  
 Not vaccinated: subjects who reported never receiving BCG vaccination. 
Self-reported history was combined with the result of inspection of the arms for a scar to 
define BCG vaccination status as detailed in the Table 5 below. Briefly, subjects with a 
convincing self-reported history of BCG, or a probable history and a scar were classified as 
vaccinated. Those with a history of no BCG vaccination and no scar at inspection, or either, 
were classified as not vaccinated.  
Those with history of vaccination reported the age when they were vaccinated, but the 
exact date of vaccination was not available, so a date of vaccination was assigned randomly 
by sampling dates within the year corresponding to the age at vaccination (excluding the 
school-holiday months of July and August), using a uniform distribution. For those in which 
the age of vaccination was not available (e.g. “possibly vaccinated” based on scar), the age 
at vaccination was assigned to be age 12 years, which was the median age at vaccination 
among those for whom age at vaccination was available. 
Table 5 Definition of BCG vaccination status for the school-age BCG study 
Self-reported history Scar inspection BCG vaccination status 
Convincing BCG history Scar present 
“Vaccinated” 
 
Convincing BCG history No scar 
Convincing BCG history Not inspected 
Probable BCG history* Scar present 
Probable BCG history* No scar 
Probable BCG history* Not inspected 
No BCG history Scar present 
Unsure Scar present 
No BCG history No scar 
“Not vaccinated” No BCG history Not inspected 
Unsure No scar 
Unsure Not inspected Missing 
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Association between time since BCG vaccination and risk of TB 
We investigated the association between time since vaccination and the risk of TB in two 
steps: 
 Firstly we estimated the association for successive time-since-vaccination intervals of 
approximately 5 years, respectively 1-5, 5-10,10-15,15-19 years after vaccination 
for the infant BCG study, and 10-15,15-20, 20-25, and 25-29 years after vaccination 
for the school-age BCG study. 
 Secondly, we modelled vaccine effectiveness smoothly as a function of  time-since-
BCG.  
Statistical methods 
The data were analysed using the case-cohort approach,36, 37 in which controls formed the 
‘sub-cohort’, i.e. the set of potential controls for each case. This provided an efficient 
analysis approach for the data which made best use of data for controls throughout the time 
they were at risk, and allowed flexible modelling of vaccine effectiveness by time since 
vaccination.38 This approach was appropriate because our controls were sampled at random 
from the underlying population within which cases arose (with frequency matching on year 
of birth) and because the outcome (TB) is rare in the underlying population (with annual TB 
notification rates in our study populations in the 10s per 100,000); the controls can 
therefore be considered approximately as random samples from the underlying population 
within each of the frequency-matching strata.  
Under our selected approach, each case is compared at its event time with all controls in 
the sub-cohort who are still at risk at that time and who are in the same stratum as the 
case. The statistical analyses assume an underlying Cox proportional hazards model, the 
parameters of which were estimated using a pseudo-partial likelihood analysis with robust 
standard errors; the latter is necessary in case-cohort analyses to account for the ‘shared’ 
control groups between cases.  
Follow-up started for all participants from the 1s t birthday (when most would have had an 
opportunity to receive infant BCG vaccination).  In both studies, the basic model for vaccine 
effectiveness was stratified by year of birth, and adjusted for sex. Allowing separate 
baseline hazards within each year of birth was used to account for frequency-matching of 
controls on year of birth. For the infant BCG study, given that not only the risk of TB in each 
ethnic group is different but also the age distribution of cases is different, the baseline 
hazard was also allowed to vary by ethnic group.  Other covariates were then added in turn 
in the basic model to assess potential confounding effect by examining changes in the point 
estimates and the standard errors, and a final multivariable model was built.  
NIHR/HTA STUDY 08/17/01 BCG duration of protection against tuberculosis in the UK 
Main studies - methods 
34 
 
We present results as hazard ratios (HRs) and corresponding 95% confidence intervals 
(95% CI). Vaccine effectiveness (VE) estimates can be computed as VE = 1 – HR). 
We modelled vaccine effectiveness smoothly as a function of time-since-BCG using two 
methods. Firstly, we used a restricted cubic spline with 3 knots, with the knots reflecting the 
time intervals of each study. Secondly, we fitted a simpler model in which the log hazard 
ratio associated with BCG vaccination was assumed to change linearly with time.  The results 
were displayed graphically as smooth curves, including 95% confidence limits.  The results 
from the linear model were also tabulated.  
 
Handling of missing data 
Results presented in this report are based on ‘complete case’ analyses. Individuals with 
missing information on vaccination status (according to our definitions) are excluded from 
analyses. Individuals with missing data on adjustment variables are excluded from models 
that include those variables. Results from models, which include different adjustment 
variables, are compared by fitting the simpler models on both the maximum possible 
number of individuals for the model in question and on the subset of individuals on which 
more fully adjusted models are fitted.  
Given the presence of some missing data especially for vaccine records, further analyses 
including use of scar information and possibly multiple imputation will be explored. They are 
not part of this report.   
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Results  
Main results from Pilot study 
The response rates were estimated respectively as 61% for the infant BCG study cases and 
35% for the school-age BCG cases (table 6). The refusal rates were similar between the two 
studies and consistent with community-based studies (about 10%), and the difference was 
mainly due to non-contact, notably because of address changes. It was not unexpected as 
the target population for the school-age BCG study included more young and middle-age 
adults of working age, hence likely to be more mobile. 
Table 6: Response rate in cases: 
Outcome Infant BCG 
Sample 
School-age BCG 
Sample 
Total Invited 58 57 
Could not be contacted (%) 17 (29%) 32 (56%) 
Contacted but refused to take part (%) 7 (12%) 6 (11%) 
Successfully recruited (%) 34 (61%) 19 (35%) 
 
Less than 1 in 4 infant BCG study cases and 1 in 3 school-age BCG study cases were willing 
and/or able to nominate 2 or more potential controls, and respectively 29% and 26% were 
unable to suggest any acquaintance (table 7). Furthermore, of the total nominated 
acquaintances, we were only able to recruit 46% (17/34) for the infant BCG study and 35% 
(8/23) for the school-age BCG study . A further challenge was the time needed to recruit 
each control, as nominated acquaintances (when more than one) could not a ll be contacted 
concomitantly.  
Table 7 Results of nominated control strategy 
Number of controls 
nominated per case 
recruited 
Infant BCG Sample 
(n=34) 
School-age BCG Sample 
(n=19) 
0 10 (29%) 5 (26%) 
1 16 (47%)  8 (42%) 
2 to 5 8 (24%) 6 (32%) 
 
The data collection tools and study procedures worked well and required only minor 
alterations. 
 
Conclusion from pilot study: 
The two main conclusions from the pilot study were:  
1. Nomination of acquaintances to recruit controls was unlikely to be effective in this 
context. The low recruitment of nominated controls by cases was partly due to the 
paucity of friends of similar age as well as not wanting to risk any potential disclosure 
of past health issues.  We decided instead to use the alternative already planned, 
community-based controls. 
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2. The low recruitment of cases in the school-BCG study (35% of those invited) 
suggested a reduction in the number of cases expected to be recruited even by 
inviting all those eligible and notified to the ETS. This led us to adjust the sample size 
by increasing the ratio of controls per case from 1 control per case to 2 controls per 
case. 
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Results: Concordance between different measures of BCG vaccination  
These results are based on eligible participants successfully recruited to the respective 
studies, as detailed in the subsequent sections. For the infant BCG study, it was found that 
participants had difficulties distinguishing BCG vaccination in infancy from other childhood 
vaccines. As the information of self-reported vaccination was clearly of poor quality, the 
three other BCG indicators were examined: scar inspection, personally-held records (red 
book or vaccination card), and NHS vaccination records. For the school-age BCG study, the 
quality of recall was better, probably because vaccination was offered at an older age, i.e. 
to schoolchildren aged 12-13 years on average.  
Availability of information on indicators of BCG status 
In the infant BCG study, respectively 15% of cases and 10% of controls declined scar 
inspection. Red books were available in 48% cases and 57% controls, and NHS records 
were found for 52% cases and 40% controls (table 8).  
In the school-age BCG study, self-reported history was available in over 95% of 
participants, and scar inspection was done in more than 90% of subjects. Vaccination 
records were unavailable for over 95% of subjects, and thus could not be used (table 9). 
Table 8 Available information on various BCG indicators by case and control in the infant 
BCG study 
Variable 
Cases 
(n=744) 
% 
Controls 
(n=694) 
% 
Red book and vaccination card 
Available: BCG vaccination not recorded 156 21.0 152 21.9 
Available: BCG vaccination recorded 203 27.3 241 34.7 
Not available 385 51.7 301 43.4 
NHS record 
Available: BCG vaccination not recorded 100 13.4 72 10.4 
Available: BCG vaccination recorded 286 38.4 209 30.1 
Not available 358 48.1 413 59.5 
Scar inspection 
BCG scar present 207 27.8 174 25.1 
No BCG scar 422 56.7 451 65.0 
Not inspected 115 15.5 69 9.9 
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Table 9 Available information on various BCG indicators by case and control in the school-
age BCG study 
Variable 
Cases 
(n=677) 
% 
Controls  
(n=1170) 
% 
Self-reported BCG history 
History of BCG  170 25.1 169 14.4 
No history of BCG 476 70.3 954 81.5 
Do not remember 31 4.6 47 4.0 
Scar inspection 
Interviewer did not find a BCG scar  204 30.1 269 23.0 
Interviewer found a BCG scar 424 62.6 844 72.1 
Not inspected 49 7.2 57 4.9 
Red book and vaccination card  
Available: BCG vaccination not recorded 29 4.3 59 5.0 
Available: BCG vaccination recorded 6 0.9 12 1.0 
Not available 642 94.8 1099 93.9 
NHS record  
Available: BCG vaccination not recorded 20 2.9 27 2.3 
Available: BCG vaccination recorded 16 2.4 20 1.7 
Not available 641 94.7 1123 96.0 
 
Agreement between NHS and BCG records, and scar and records in the infant BCG study 
The agreement in BCG vaccination between NHS records and Red book was poor (table 11), 
suggesting different patterns of incompleteness in the two types of records (i.e. it was 
unlikely that the absence of BCG in one record equated to no vaccination). We found that 
40% (35/88) of subjects with no BCG in their NHS records were vaccinated according to 
their red book, and 67% (110/163) of those with no BCG in their red book were vaccinated 
according to their NHS record.  
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Table 10 Agreement between NHS and BCG records in the infant BCG study  
  BCG in red book 
BCG in NHS 
Record 
Overall Cases Controls 
No Yes No Yes No Yes 
No 
53 
(14.6%) 
35 
(9.9%) 
35 
(17.4%) 
18 
(9.0%) 
18 
(11.5%) 
17 
(10.8%) 
Yes 
110 
(30.8%) 
160 
(44.8%) 
61 
(30.3%) 
87 
(43.3%) 
49 
(31.2%) 
73 
(46.5%) 
Kappa 0.15 0.20 0.09 
 
The data also suggested that for infant vaccination scar inspection was not very specific as 
compared to vaccination records (table 12). Respectively of those with no BCG in their Red 
book only 42% (111/262) subjects had no scar, and of subjects with no BCG in their NHS 
records, only 40% (58/146) had no scar on inspection. This proportion was slightly higher 
when we combined records and considered no BCG in both records as our best evidence of 
unvaccinated status; 53% (23/43) of those thus classified as unvaccinated had no scar at 
inspection.  
Table 11 Concordance between scar inspection and vaccination records1 in the infant BCG 
study, overall and by case and control status 
Scar 
inspection 
Red book NHS records Combined records 
BCG 
recorded 
BCG not 
recorded 
BCG 
recorded 
BCG not 
recorded 
BCG 
recorded 
No BCG in 
both 
Cases n = 182 n = 130 n = 248 n = 80 n = 351 n = 28 
Scar 
present 
128 
(70.3%) 
76 
(58.5%) 
183 
(73.8%) 
47 
(58.7%) 
252 
(71.8%) 
14 (50%) 
Scar absent 
54 
(29.7%) 
54 
(41.5%) 
65 
(26.2%) 
33 
(41.3%) 
99 
(28.2%) 
14 (50%) 
Controls n = 226 n = 132 n = 188 n = 66 n = 346 n = 15 
Scar 
present 
184 
(81.4%) 
75 
(56.8%) 
152 
(80.8%) 
41 
(62.1%) 
280 
(80.9%) 
6 (40%) 
Scar absent 
42 
(18.6%) 
57 
(43.2%) 
36 
(19.2%) 
25 
(37.9%) 
66 
(19.1%) 
9 (60%) 
Overall n = 408 n = 262 n = 436 n = 146 n = 697 n = 43 
Scar 
present 
312 
(76.5%) 
151 
(57.6%) 
335 
(76.8%) 
88 
(60.3%) 
532 
(76.3%) 
20 
(46.5%) 
Scar absent 
96 
(23.5%) 
111 
(42.4%) 
101 
(23.2%) 
58 
(39.7%) 
165 
(23.7%) 
23 
(53.5%) 
1Subjects are vaccinated if BCG reported in either record. They are unvaccinated if both records and 
available and neither have BCG reported. 
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Agreement between BCG history and scar in the school-age BCG study 
 
There was good agreement between self-reported history of BCG and scar inspection among 
participants to the school-age BCG study (kappa=0.6; table 10)  
 
   
Table 12 Agreement between BCG self-reported history and scar in school-age BCG study 
  Self-reported history of BCG vaccination 
Scar 
inspection 
Overall Cases Controls 
Yes No Yes No Yes No 
Scar Present 
1181 
(70.5%) 
43 
(2.6%) 
394 
(65.1%) 
16 
(2.6%) 
787 
(73.5%) 
27 
(2.5%) 
No scar 
195 
(11.6%) 
257 
(15.3%) 
60 
(9.9%) 
135 
(22.3%) 
135 
(12.6%) 
122 
(11.4%) 
Kappa 0.60 0.69 0.52 
 
 
Interpretation:  
Our information about BCG vaccination was clearly better in the school vaccination than for 
infant vaccination.  
For the infant BCG study, it appears that no single indicator of BCG status was good enough 
to be used on its own to define BCG vaccination status, our main exposure. There was some 
suggestion that combining information from both records was helpful. For the school-age 
study, data were available on two main indicators, respectively self-reported history and 
scar inspection, and there was good agreement between both measures. This suggested 
they could be combined to better define BCG vaccination status.  
 
Results:  Infant BCG study 
Overview of recruitment 
Recruitment of cases 
Of 1390 potentially eligible cases from the ETS invited to take part in the study, it was 
possible to contact 1138. Of these 6% were also excluded either because they were not 
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born in the UK, they were away as reported by a household member, or during interview 
were noted to have been vaccinated because of contact with a case of TB. Of the 1076 
subjects contacted and eligible, 797 (74%) subjects were enrolled.  
 
 
Figure 3 Overview of infant BCG cases recruitment 
1No contact because changed addresses (142), no contact with anybody at address provided (87), 
moved out of England to other parts of UK (10), moved abroad (8), unspecified (5). 
2Ineligible (29) because not born in the UK (20), not BAME (2) reported contact with TB case in red 
book and consistent with date TB diagnosis in ETS (2), unspecified (5). 
3Other difficulties (33) include away or in hospital during the survey (22), too frail to take part (5) and 
various other reasons (6). 
4Note 797 cases successfully recruited, but 53 not included in analysis because developed TB before 
chance of getting infant BCG (i.e before 1st birthday)  
 
Recruitment of controls 
We sampled 7755 residential addresses, of which 1089 (14%) could not be screened to 
establish eligibility for the study because addresses could not be located or were 
inaccessible, or where no contact could be established following the standard visit pattern of 
visiting more than once on different days and more than once at different times.  Among 
the 6666 addresses that were screened, 1073 (16%) had at least one eligible resident, with 
694 (65%) eligible subjects successfully recruited to the control group. 
1390 cases identified from ETS 
2003-2012 
No contact
1
 
made: 252 
(18.1%) 
Ineligible2 / Other3 
difficulties: 62 (5.4%) 
Refused:         
279 (25.9%) 
Eligible:      
 1076 (94.6%) 
Contact made: 
1138 (81.9%) 
Successful
4
:       
797 (74.1%) 
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Figure 4 Overview of infant BCG study recruitment of controls 
1Not screened because no contact with anybody at address provided after several visits following pre-
set visit pattern. 
2Ineligible include 4861 addresses screened with no eligible subjects and 719 addresses either with 
non-residential, vacant, derelict or demolished buildings. 
 
Comparison of recruitment between cases and controls 
The proportion of cases that could be contacted was fairly comparable across quintiles of 
area-level indices of multiple deprivation (IMD) (table 13). Among those contacted and 
eligible, the refusal rate did not vary much by quintile of area-level IMD. Similarly, the 
proportion of addresses successfully screened was similar across quintiles of IMD. Among 
subjects identified as eligible to be controls, the refusal rate had a similar trend as in cases, 
but was consistently higher in controls than cases.  
 
Table 13: contact and refusal rates in infant BCG study by area-level indices of deprivation 
quintiles and case/control status 
 Cases  Controls 
 Cases invited to participate Addresses screened for eligible 
IMD quintiles Total Contacted Total Screened 
Least deprived 159 134 (84%) 1556 1377 (88%) 
2 219 174 (79%) 1559 1379 (88%) 
3 273 217 (79%) 1544 1305 (84%) 
4 330 283 (86%) 1547 1307 (84%) 
Most deprived 407 328 (91%) 1549 1298 (84%) 
 Eligible cases contacted Eligible controls contacted 
IMD quintiles Eligible Refusal Eligible Refusal 
Least deprived 125 38 (30%) 217 82 (38%) 
2 160 42 (26%) 223 87 (38%) 
3 205 55 (27%) 186 65 (35%) 
4 271 67 (25%) 197 71 (36%) 
Most deprived 312 76 (24%) 250 74 (30%) 
 
Included:        
694 (64.7%) 
7755 household addresses 
sampled 
Not screened1: 
1089 (14.0%) 
Screened:     
6666 (86.0%) 
Eligible:         
1073 (16.1%) 
Ineligible2:           
5593 (83.9%) 
Refused:         
379 (35.3%) 
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The distribution of visits by time of the day and by day of the week was also comparable in 
cases and controls (figure 6). 
 
 
Figure 5 Distribution of interviewers visits by time of the day, and day of the week in invited 
cases and sampled control addresses for the infant BCG study 
 
Fifty-three subjects who had developed TB in their 1s t year of life were censored  (i.e. exited 
the study) before the start of ‘follow-up’, as some may have developed TB before full 
opportunity for infant-BCG vaccination (which could have been offered at any point before 
age one year), hence they were not included in the analysis. Table 14 shows the number of 
cases by age-range at the time of TB diagnosis and birth cohort.  
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Table 14 Distribution of cases and controls in the infant BCG study by time-intervals since 
vaccination 
 
Number of cases1 by birth cohort and age-range (in years) at 
time of TB diagnosis, and number of controls2 from the same 
birth cohort 
Birth cohort  Total 1-4  5-9  10-14 15-19 
1985-1989 
Cases 54 - - 9 45 
Controls 67 0 0 33 67 
1990-1994 
Cases 188 - 2 72 114 
Controls 130 0 55 130 130 
1995-1999 
Cases 202 3 59 109 31 
Controls 151 61 151 151 90 
2000-2004 
Cases 189 93 73 17 - 
Controls 168 168 168 56 0 
2005-2011 
Cases 117 103 14 - - 
Controls 178 178 67 0 0 
1
Note that the study included cases notified between 2003 and 2012 and aged 1 to 19 years at time of diagnosis; 
therefore some b irth cohorts do not contribute cases in some follow-up time (left-truncation. e.g. b irth cohort 1985-
1989 would be aged 13-19 years at start of ‘follow-up’ in 2003, so will not include subjects from the b irth cohort who 
developed TB at age 1-12 years) 
2
Controls could contribute observation time to more than one period since vaccination (see methods section for 
details)  
 
Descriptive statistics by case and control status 
The distribution of cases and controls by sex and birth cohort did not appear substantially 
different although there were more cases with Pakistani and Black African ethnic 
background (63%) than controls (44%) (Table 15). The distributions of TB cases by area-
level deprivation quintiles and highest level of parental education were consistent with the 
known relationship between TB and deprivation, with increasing proportion of cases in the 
more deprived quintiles, and having parents with fewer educational qualifications. The 
proportion of cases from overcrowded households was also higher than in controls. The 
distribution of other variables was fairly similar. In addition, nearly 95% of study 
participants had a place of residence in infancy or early childhood where infant BCG 
vaccination was offered, and was similar in cases and controls. 
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Table 15 Characteristics of subjects in the infant BCG study by case and control status 
Characteristic Cases1 
(n=744) 
% Controls 
(n=694) 
% 
Birth Cohort 
1985-1989 54 7.3 67 9. 6 
1990-1994 188 25.3 130 18.7 
1995-1999 202 27.1 151 21.8 
2000-2004 183 24.6 168 24.2 
2005-2011 117 15.7 178 25.7 
Sex 
Female 417 56.1 350 50.4 
Male 327 43.9 344 49.6 
Ethnicity  
Indian + mixed  146 19.6 172 24.8 
Bangladeshi + mixed  55 7.4 79 11.4 
Pakistani + mixed 323 43.4 206 29.7 
Other Asian + mixed 27 3.6 51 7.4 
Black African + mixed 150 20.2 97 14.0 
Other Black + mixed 43 5.8 89 12.8 
Quintiles of LSOA-level Index of Multiple Deprivation 
1 (least deprived) 86 11.6 139 20.0 
2 105 14.1 140 20.2 
3 182 24.5 139 20.0 
4 199 26.7 141 20.3 
5 (most deprived) 172 23.1 135 19.5 
Parental highest educational (academic, professional and or vocational)  qualification 
None 263 35.3 154 22.2 
O Levels or equivalent2 214 28.8 160 23.0 
A Levels or equivalent3 88 11.8 89 12.8 
Degree level or equivalent4 142 19.1 270 38.9 
Missing 37 5.0 21 3.0 
Average number of people per room 
Less than or equal to 1 524 70.4 569 81.8 
Greater than 1 191 25.7 126 18.2 
Missing 29 3.9 0 0.0 
Average number of people per bedroom 
Less than or equal to 1 104 14.0 168 24.2 
Greater than 1 610 82.0 526 75.8 
Missing 32 4.0 0 0.0 
TB infection risk from regular travels abroad 
Low5 453 60.9 434 62.5 
High6 289 38.8 260 37.5 
Missing 2 0.3 0 0.0 
TB infection risk from long-term stays abroad 
Low5 637 85.6 618 89.1 
High6 106 14.3 76 10.9 
Missing 1 0.1 0 0.0 
Infant BCG vaccination policy in health district / primary care trust of residence up to age 
4 years old 
None 34 4.5 39 5.6 
Selective 502 67.5 420 60.5 
Universal 186 25.0 206 29.7 
Missing 22 3.0 29 4.2 
3-year average TB notification rate in local authority or PCT of residence in childhood 
<20 per 100,000 172 23.1 177 25.5 
20  to 39 per 100,000 394 53.0 299 43.1 
40 per 100,000 or higher 178 23.9 216 31.1 
Missing 0 0.0 2 0.3 
153 cases with TB in their first year of life exit before the start of follow-up at the 1st birthday 
2O Levels, GCEs, or GCSEs (any grades), City & Guilds Craft/Ordinary Level or NVQ Level 1 or 2  
3 A Levels, SCE Higher, ONC/ONT/BEC/TEC, City & Guilds Advanced Final Level or NVQ Level 3 
4Degree Level, Teaching qualification, HNC/HND, BEC/TEC Higher or BTEC Higher  
5 Regular travel (i.e. every few years or more often) or long-term (>3 months) stay to Eastern Europe, Caribbean, 
or none of the places specified 
6 Regular travel (i.e. every few years or more often) or long-term (>3 months) stays to Africa or Asia 
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Indicators of vaccination status 
We examined our main definition of BCG vaccination status combining information from the 
Red book and NHS records (see table 4). The distribution of BCG status according to these 
definitions by case and control status is presented in table 16. The detailed uptake in cases 
and controls is presented in table 17, for each interval of time since vaccination and by birth 
cohort stratum; in the analysis, we stratified by year of birth.  
 
Table 16: BCG vaccination status in the infant BCG study based on combination of Red book 
and NHS records 
Red Book NHS Record 
BCG vaccination 
status (def 1) 
Cases 
(n=744) 
Controls 
(n=694) 
BCG Recorded BCG Recorded 
Vaccinated 402 (54.0%) 377 (54.3%) 
BCG Recorded BCG not recorded 
BCG recorded Missing 
BCG not recorded BCG Recorded 
Missing BCG Recorded 
BCG not recorded  BCG not recorded Not vaccinated 35 (4.7%) 18 (2.6%) 
BCG not recorded Missing 
Missing  
60 (8.1%) 85 (12.3%) 
Missing BCG not recorded 47 (6.3%) 37 (5.3%) 
Missing Missing Missing 200 (26.9%) 177 (25.5%) 
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Association between time since BCG and all TB: complete case analysis 
Table 17 Distribution of observed vaccination status (definition: combined BCG records) by 
cases and corresponding sub-cohort of controls in the infant BCG study 
 Vaccination status in cases by birth cohort and age-range (in years) at 
time of TB diagnosis, and in controls1 from the same birth cohort 
  Uptake by time since vaccination (in years)  
Birth 
cohort 
 Total 1-5  5-10  10-15 15-19 
       
1985-1989 
Cases vaccinated 16/17 (94%) 0 0 2/3 14/14 
Controls 
vaccinated 
15/16 (94%) 0 0 6/7 15/16 
1990-1994 
Cases vaccinated 78/85 (92%) 0 1/1 27/31 50/53 
Controls 
vaccinated 
46/48 (96%) 0 19/21 46/48 46/48 
1995-1999 
Cases vaccinated 
118/125 
(94%) 
3/3 38/39 62/67 15/16 
Controls 
vaccinated 
86/90 (95%) 40/41 86/90 86/90 46/49 
2000-2004 
Cases vaccinated 
107/121 
(88%) 
56/62 42/49 9/10 0 
Controls 
vaccinated 
97/102 
(96%) 
97/102 97/102 24/27 0 
2005-2011 
Cases vaccinated 83/89 (93%) 73/78 10/11 0 0 
Controls 
vaccinated 
133/139 
(96%) 
133/139 48/53 0 0 
Total for each time 
since BCG, across 
birth cohorts 
Cases vaccinated 
132/143 
(92.3%) 
91/100 
(91.0%) 
100/111 
(90.1%) 
79/83 
(95.2%) 
Controls vaccinated 
270/282 
(95.7%) 
250/266 
(94.0%) 
162/172 
(94.2%) 
107/113 
(94.7%) 
1Note: Controls could be used more than once hence columns by time since vaccination for controls will not add up 
to the column totals for controls (see methods section for details)  
 
Potential confounding variables 
There was little evidence of variation in vaccine uptake with covariates in the study dataset. 
There was some evidence of different uptake by ethnic background, and of higher vaccine 
uptake in participants from crowded household (table 18). We did not find strong correlation 
between covariates. 
The analyses were stratified by year of birth and ethnic background, thus allowing for the 
change in TB rates with age, as well as the known variation in TB rates between ethnic 
groups.39 The latter also accounted for any differential uptake in vaccine between ethnic 
NIHR/HTA STUDY 08/17/01 BCG duration of protection against tuberculosis in the UK 
Results infant BCG study 
48 
 
groups. In the multivariable analysis, we adjusted for those variables associated with 
vaccine uptake as well as other potential confounders, as detailed in the methods section. 
 
 
Table 18 Association between vaccine uptake (based on combined records) and covariates 
in the control group of the infant BCG study 
 
# vaccinated (%) OR 95% CI p-val 
Sex 
Female (n=193) 182 (94.3%) 1 
 0.286 
Male (n=202) 195 (96.5%) 1.68 (0.64, 4.44) 
Birth Cohort 
1985-1989 (n=16) 15 (93.7%) 1 
 
0.997 
1990-1994 (n=48) 46 (95.8%) 1.53 (0.13, 18.1) 
1995-1999 (n=90) 86 (95.6%) 1.43 (0.15, 13.7) 
2000-2004 (n=102) 97 (95.1%) 1.29 (0.14, 11.8) 
2005-2011 (n=139) 133 (95.7%) 1.48 (0.17, 13.11) 
Ethnic group 
Indian (n=96) 93 (96.9%) 1 
 
 
Bangladeshi (n=50) 48 (96.0%) 0.77 (0.13, 4.8) 
0.007 
Pakistani (n=133) 131 (98.5%) 2.11 (0.35, 12.9) 
Other Asian (n=30) 30 (100%) - - 
Black African (n=56) 50 (89.3%) 0.27 (0.06, 1.12) 
Other Black (n=30) 25 (83.3%) 0.16 (0.04, 0.72) 
Area-level deprivation quintiles 
Least deprived (n=78) 74 (94.9%) 1 
 
0.56 
2 (n=79) 77 (97.5%) 2.08 (0.37, 11.7) 
3 (n=73) 68 (93.1%) 0.73 (0.19, 2.8) 
4 (n=80) 78 (97.5%) 2.11 (0.37, 11.8) 
Most deprived (n=85) 80 (94.1%) 0.86 (0.22, 3.3) 
People per bedroom 
<1 PPB (n=75) 67 (89.3%) 1 
 0.011 
>1 PPB (n=320) 310 (96.9%) 3.70 (1.41, 9.73) 
Highest parental education level 
None (n=90) 87 (96.7%) 1 
 
0.56 
O Levels (n=87) 82 (94.2%) 0.56 (0.13, 2.4) 
A Levels (n=52) 51 (98.1%) 1.76 (0.18, 17.4) 
Degree (n=160) 151 (94.4%) 0.58 (0.15, 2.2) 
 
 
NIHR/HTA STUDY 08/17/01 BCG duration of protection against tuberculosis in the UK 
Results infant BCG study 
49 
 
Table 19: Complete case analysis of the association between time since vaccination and risk of TB using combined records in the infant BCG 
study 
 Base1 model 
(Based on 417 cases and 382 controls) 
Base1 model restricted to 
subjects with no missing data on 
covariates 
(Based on 379 cases and 378 controls) 
Multivariable2 adjusted model 
(Based on 379 cases and 378 controls) 
 HR 95% CI p-value HR 95% CI p-value HR 95% CI 
p-
value 
Unvaccinated  1 (ref)   1 (ref)      
Vaccinated: 1-5 yrs  0.38 (0.17,0.86) 0.021 0.43 (0.18,1.03) 0.058 0.34 (0.15,0.78) 0.011 
Vaccinated: 5-10 yrs 0.37 (0.15,0.88) 0.025 0.32 (0.13,0.79) 0.014 0.25 (0.11,0.56) 0.001 
Vaccinated: 10-15 yrs 0.50 (0.22,1.13) 0.096 0.68 (0.28,1.66) 0.396 0.64 (0.24,1.68) 0.361 
Vaccinated: 15-20 yrs 1.25 (0.28,5.64) 0.775 2.06 (0.33,12.91) 0.440 2.26 (0.34,15.10) 0.400 
       
      1Base model is stratified on year of b irth and ethnic group, and additionally adjusted for sex 
       
2
The multivariab le model is additionally adjusted for people-per-bedroom, area-level deprivation quintiles, and highest parental educational level  
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The results of the complete case analysis (i.e. using only subjects with vaccine records) are 
presented in table 19.  Good evidence of a protective effect of the vaccine was noted in the 
< 5 year time period and in the 5-10 year period before and after adjusting for confounding 
(HRadj=0.34 95%CI 0.14,0.78:p=0.011 and HRadj 0.25 95%CI 0.11,0.57:p=0.001 
respectively). The evidence for a protective effect of the vaccine in the time period 10-15 
years was weaker both in the baseline analysis but more so in the adjusted analysis 
(HRbaseline 0.5 95%CI 0.22,1.13: p=0.096 and HRadj 0.64 95%CI 0.24,1.68: p=0.361).  
Examination in a baseline analysis of the effect of vaccination on the smaller number of 
records used in the multivariable analysis suggested that this lack of evidence of an effect 
was the result of chance (sampling error), rather than the effect of controlling for 
confounding. Evidence was lacking for a protective effect 15 to 20 years after infant 
vaccination in both models based on the small numbers available. Confidence intervals were 
wide, ranging in the baseline analysis from 0.28 to 5.64.  
 
Trends in the association between time since BCG vaccination and risk of TB  
Table 20 shows the results from modelling the association between BCG vaccination and log 
hazard of TB as a linear function of time since vaccination, centred at 5 years post-
vaccination. The results are displayed graphically in figure 7. The model suggests an 12% 
increase in the HR with each year post-vaccination, though this was only of borderline 
statistical significance (95% CI: -1% to 26%). We also explored the trend in time using 
restricted cubic splines with 3 knots, respectively at 5, 10 and 15 years post -vaccination. 
The results were similar to those found using the linear model and are not shown here. The 
results suggest a statistically significant protective effect of the vaccine up to about 10 
years post-vaccination, with a gradual reduction in the protective effect up to that time. 
After 10 years post-vaccination, the confidence bounds are wide and there is insufficient 
information to draw conclusions about the vaccine effectiveness.  
Table 20: Association between BCG status and risk of TB in the infant BCG study as a 
smooth function of time since vaccination, using the multivariable adjustment model.  
 HR 95% CI p-val 
Unvaccinated 1 (ref)   
 HR at 5-years post-
vaccination 
0.32 (0.16,0.64) 0.001 
Multiplying factor for 
each year increase in 
time-since-vaccination 
1.12 (0.99,1.26) 0.062 
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Figure 6: Results from modelling the time-varying effect of the vaccine as a linear function 
of time (on the log scale) in the infant BCG study  
The left-hand vertical axis shows the hazard ratio (HR) and the right-hand vertical axis shows the 
vaccine effectiveness (VE), both on the log scale. Results are based on the multivariable adjusted 
model. 
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Results:  School-age BCG study 
Overview of recruitment 
Recruitment of cases 
A total of 1602 potentially eligible cases were identified from the ETS and invited to take 
part in the study, of whom 1047 (65%) were successfully contacted. About 11% were not 
included either because they were ineligible or due to other difficulties (figure 8). Of those 
contacted and eligible, 257 (28%) declined to participate and 677 (72%) subjects were 
enrolled.  
 
Figure 7 Overview of school-age BCG study cases recruitment 
 
1No contact because changed addresses (353), no contact with anybody at address provided (165),  
moved out of England to other parts of UK (10), moved abroad (12), inaccessible (6), unspecified (9). 
2Ineligible (60) because not born in the UK (13), not White (23), reported vaccination at later age and 
following contact with TB case in red book and consistent with date TB diagnosis in ETS (4), 
unspecified (20). 
3Other difficulties (53) include away or in hospital during the survey (23), too frail to take part (20), 
who had died (6), other reasons (4). 
 
Recruitment of controls 
We sampled 9424 residential addresses, of which 1248 (13%) could not be screened 
because the address no longer existed or no-one was at the household after several visits to 
establish whether any of the residents was eligible for the study (figure 8). Among the 8176 
addresses that were screened, 1790 (22%) had at least one eligible resident, with 1170 
(65%) eligible subjects successfully recruited to the control group. 
  
1602 cases identified from ETS 
2003-2012 
No contact
1
 made: 
555 (34.6%) 
Ineligible2 / Other 
difficulties3:   113 (10.8%) 
Refused:          
257 (27.5%) 
Eligible:      
 934 (64.7%) 
Contact made: 
1047 (65.4%) 
Successful:      
677 (72.5%) 
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Figure 8 Overview of school-age BCG study recruitment of controls 
1No screened because no contact with anybody at address provided after several visits following pre-
set visit pattern. 
2Ineligible include 5692 addresses screened with no eligible subjects and 694 addresses either with 
non-residential, vacant, derelict or demolished buildings. 
 
Comparison of recruitment between cases and controls 
The proportion of cases that could be contacted was slightly lower in the more deprived 
quintiles of area-level indices of multiple deprivation (table 21). Among those contacted and 
eligible, the refusal rate was slightly lower in the lower quintiles of area-level IMD. The 
proportion of addresses to identify eligible controls successfully screened was similar across 
quintiles of IMD. Among subjects identified as eligible to be controls, the refusal rate was 
similar across quintiles and was slightly higher in controls than cases. 
Table 21: Comparison of recruitment in school-age BCG study cases and controls  
 Cases  Controls 
 Cases invited to participate Addresses screened for eligible 
IMD quintiles Total Contacted Total contacted 
Least deprived 165 119 (72%) 1889 1634 (87%) 
2 218 157 (72%) 1885 1599 (85%) 
3 233 148 (64%) 1886 1631 (86%) 
4 394 254 (64%) 1886 1659 (88%) 
Most deprived 575 357 (62%) 1878 1653 (88%) 
 Eligible cases contacted Eligible controls contacted 
IMD quintiles Eligible Refusal Eligible Refusal 
Least deprived 107 35 (33%) 429 155 (36%) 
2 146 36 (25%) 363 130 (36%) 
3 137 35 (26%) 358 127 (35%) 
4 217 63 (29%) 359 113 (31%) 
Most deprived 316 86 (27%) 281 95 (34%) 
Successful:        
1170 (65.4%) 
9424 household addresses 
sampled 
Not screened: 
1248 (13.2%) 
Screened: 8176 
(86.8%) 
Eligible:          
1790 (21.9%) 
Ineligible:       
6386 (78.1%) 
Refused:         
620 (34.6%) 
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The distribution of visits by time of the day and by day of the week was comparable in cases 
and controls (figure 9). 
 
Figure 9 Distribution of interviewers’ visits by time of the day, and day of the week in 
invited cases and sampled control addresses for the school-age BCG study 
 
We found that retrospective ascertainment of results of TST testing was challenging in the 
school-aged BCG vaccine study, with very poor recall and with no record to support or 
validate participants’ self-reports. Further investigation of the literature indicated that the 
initially high TB risk in those who were PPD positive dropped to be the same as those PPD 
negative unvaccinated (figure 12). Thus, we included all those unvaccinated irrespective of 
PPD status prior to the offer of school-aged BCG vaccination.  
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Descriptive statistics by case and control status 
The cases were slightly younger than controls and more likely to be male (table 22). The 
distributions of cases compared to controls by area-level deprivation quintiles and highest 
level of education were consistent with the known association of TB with deprivation, with a 
higher proportion of cases in the most deprived quintile, and with fewer educational 
qualifications compared to controls. The proportion of cases from overcrowded households 
was also slightly higher than controls. Cases were slightly more likely to have had regular 
travel to a high-risk area and somewhat more likely to have had a long term stay in a high 
risk area. A higher proportion of cases than controls reported drinking at a hazardous or 
harmful level and reported being a smoker. A much higher proportion of cases than controls 
reported having used class A drugs. Cases were also more likely than controls to report a 
history of homelessness for a week or more, and prison detention in the UK or abroad. 
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Table 22 Characteristics of study participants in school-age BCG study by case and control 
status 
Characteristic Cases 
(n=677) 
% Controls 
(n=1170) 
% 
Birth Cohort 
1965-1969 65 9.6 174 14.9 
1970-1974 178 26.3 312 26.7 
1975-1979 215 31.8 260 22.2 
1980-1989 219 32.3 424 36.2 
Sex 
Female 341 50.4 700 59.8 
Male 336 49.6 470 40.2 
Quintiles of LSOA-level Index of Multiple Deprivation 
1 (least deprived) 63 9.3 234 20.0 
2 99 14.6 234 20.0 
3 109 16.1 234 20.0 
4 130 19.2 234 20.0 
5 (most deprived) 276 40.8 234 20.0 
Highest educational (academic, professional and or vocational)  qualification  
None 132 19.5 75 6.4 
O Levels or equivalent1 207 30.6 363 31.0 
A Levels or equivalent2 91 13.4 246 21.0 
Degree level or equivalent3 216 31.9 455 38.9 
Missing 31 4.6 31 2.7 
Average number of people per room 
Less than or equal to 1 634 93.7 1144 97.8 
Greater than 1 26 3.8 24 2.0 
Missing 17 2.5 2 0.2 
Average number of people per bedroom 
Less than or equal to 1 385 56.9 705 60.3 
Greater than 1 275 40.6 463 39.6 
Missing 17 2.5 2 0.2 
TB infection risk from regular travels abroad  
Low4 618 91.3 1099 93.9 
High5 58 8.6 71 6.1 
Missing 1 0.1 0 0.0 
TB infection risk from long-term stays abroad 
Low4 607 89.7 1113 95.1 
High5 70 10.3 57 4.9 
Alcohol drinking6 
Very low/no risk 166 24.5 329 28.1 
Low risk 346 51.1 632 54.0 
Hazardous risk 36 5.3 68 5.8 
Harmful risk 41 6.1 25 2.2 
Missing 88 13.0 116 9.9 
Tobacco smoking 
Never smoker 188 27.8 499 42.6 
Ex-smoker 62 9.2 135 11.5 
Smoker: <20 pack-years 308 45.5 422 36.1 
Smoker: >=20 pack-years 99 14.6 85 7.3 
Missing 20 2.9 29 2.5 
Drug misuse/abuse7 
No drug use 379 56.0 847 72.4 
Class B and/or C use only 69 10.2 108 9.2 
Class A use  217 32.0 188 16.1 
Missing 12 1.8 27 2.3 
History of homelessness 
Never been homeless for >1 week 553 81.7 1091 93.2 
Ever been homeless for >1 week 117 17.3 68 5.8 
Missing 7 1.0 11 0.9 
History of prison stay8 
Never detained 590 87.2 1119 95.6 
Ever detained in the UK or abroad 82 12.1 35 3.0 
Missing 5 0.7 16 1.4 
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1O Levels, GCEs, or GCSEs (any grades), City & Guilds Craft/Ordinary Level or NVQ Level 1 or 2 
2 A Levels, SCE Higher, ONC/ONT/BEC/TEC, City & Guilds Advanced Final Level or NVQ Level 3 
3Degree Level, Teaching qualification, HNC/HND, BEC/TEC Higher or BTEC Higher 
4Regular travel (i.e. every few years or more often) or long-term (>3 months) stay to Eastern Europe, 
Caribbean, or none of the places specified 
5Regular travel (i.e. every few years or more often) or long-term (>3 months) stays to Africa or Asia 
6Alcohol drinking based on combination on drinking frequency and quantity in UK standard units, and 
cut-offs by gender as proposed by Rehm et al.(IJE 1999) 40. Cut-offs for hazardous and harmful 
drinking respectively (20g/day and 40g/day) in women and (40g/day and 60g/day) in men. Subjects 
who stopped drinking 5 years or more ago classified as low risk.   
7Class B and C examples included benzodiazepines, cannabis, qat, glue, gas, solvents, and 
amphetamines. Class A drug examples included ecstasy, cocaine, crack, heroin, LSD, magic 
mushrooms 
872/82 (88%) cases and 33/35 (94%) controls with history of prison stay report only ever been in 
prison in the UK and not abroad.  
 
Indicators of vaccination status 
The availability of the various indicators of BCG status is presented in table 23. As noted, 
earlier in table 12 page 40, self-report of BCG vaccination at school was judged to be more 
accurate than a self or parental report of infant BCG vaccination. Both personal and NHS 
records were missing for over 90% study participants in the school-aged BCG vaccination 
study and insufficient to allow any formal assessment of the validity of either of these 
measures.  There was however, a good level of agreement between self-reported history 
and scar inspection. These two indicators were therefore combined to define BCG status in 
this study (table 24).  
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Table 23 Availability of BCG indicators in school-age BCG study by case and control status 
 Cases (n=677) Controls (n=1170) 
BCG history 
Vaccinated 470 (69.4%) 922 (78.8%) 
Probably vaccinated 6 (0.9%) 32 (2.7%) 
Not vaccinated 170 (25.1%) 169 (14.4%) 
Missing 31 (4.6%) 47 (4.0%) 
Scar inspection 
Scar present 424 (62.6%) 844 (72.1%) 
Scar absent 204 (30.1%) 269 (23.0%) 
Not inspected 49 (7.2%) 57 (4.9%) 
Personal vaccination record 
BCG recorded 6 (0.9%) 12 (1.0%) 
BCG not recorded 29 (4.3%) 59 (5.0%) 
No personal record  642 (94.8%) 1099 (94.0%) 
NHS vaccination records 
BCG recorded 16 (2.4%) 20 (1.7%) 
BCG not recorded 20 (2.9%) 27 (2.3%) 
NHS record missing 641 (94.7%) 1123 (96.0%) 
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Table 24: BCG vaccination status in school-age BCG study based on combination of self-
report and scar reading 
Self-reported 
history 
Scar inspection 
BCG 
vaccination 
status 
Cases 
(n=677) 
Controls 
(n=1170) 
Convincing BCG 
history 
Scar present 
“Vaccinated” 473 (69.9%) 933 (79.7%) 
Convincing BCG 
history 
No scar 
Convincing BCG 
history 
Not inspected 
Probable BCG history Scar present 
Probable BCG history No scar 
“likely 
vaccinated”* 
33 (4.9%) 78 (6.7%) 
Probable BCG history Not inspected 
No BCG history Scar present 
Unsure Scar present 
No BCG history No scar 
“Not 
vaccinated” 
163 (24.1%) 154 (13.2%) No BCG history Not inspected 
Unsure No scar 
Unsure Not inspected Missing 8 (1.2%) 5 (0.4%) 
*sensitivity analysis moving this category to the vaccinated did not change the effect estimate of the 
association between BCG and TB and had small numbers, they were therefore assigned to the 
vaccinated category in the rest of the results  
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Association between time since BCG and all TB: complete case analysis 
Table 25 Distribution of observed vaccination status in school-age BCG study (combined 
BCG history and scar) by cases and corresponding sub-cohort of controls 
 Vaccination status in cases by birth cohort and age-range (in years) at 
time of TB diagnosis, and in controls1 from the same birth cohort 
  Uptake by time since vaccination (in years)  
Birth 
cohort 
 Total 10-15   15-20  20-25 25-29 
1965-1969 
Cases vaccinated 51/64 (79.7%) - - 32/39 19/25 
Controls vaccinated 
147/173 
(85.0%) 
0 0 124/144 147/173 
1970-1974 
Cases vaccinated 
136/174 
(78.2%) 
- 28/34 93/120 15/20 
Controls vaccinated 
262/311 
(84.2%) 
0 208/259 262/311 262/311 
1975-1979 
Cases vaccinated 
161/212 
(75.9%) 
33/46 66/81 61/84 1/1 
Controls vaccinated 
231/259 
(89.2%) 
231/259 231/259 231/259 55/64 
1980-1989 
Cases vaccinated 
158/219 
(72.2%) 
121/159 37/59 0/1 - 
Controls vaccinated 
371/422 
(87.9%) 
371/422 236/259 48/55 0 
Total for each time 
since BCG, across 
birth cohorts 
Cases vaccinated 
154/205 
(75.1%) 
131/174 
(75.3%) 
186/244 
(76.2%) 
35/46 
(76.1%) 
 
1Note: Controls could be used more than once hence columns by time since vaccination for controls will not add up 
to the column totals for controls (see methods section for details) 
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Table 26 Complete case analysis of the association between time since vaccination and risk of TB using various definitions for BCG status in 
the school-age BCG study 
 
 Base0 model 
(based on 669 cases and 
1165 controls) 
Partially1 adjusted 
model 
(based on 638 cases and 
1134 controls) 
 
Fully2 adjusted model 
(based on 532 cases and 
993 controls) 
Base0 model fitted on 
same subset as 
included in fully2 
adjusted model 
(based on 532 cases and 
993 controls) 
 
Partially1 adjusted 
model fitted on same 
subset as included in 
Fully2 adjusted model 
(based on 532 cases and 
993 controls) 
 HR 95% CI p-val HR 95% CI p-val HR 95% CI p-val HR 95% CI p-val HR 95% CI p-val 
Unvaccinated 
1 
(ref) 
  
1 
(ref) 
  
1 
(ref) 
  
1 
(ref) 
  
1 
(ref) 
  
Vaccinated: 
10-15 yrs ago 
0.400 (0.274,0.584) 0.000 0.419 (0.272,0.644) 0.000 
0.49 (0.31,0.79) 0.003 0.43 (0.28,0.66) <0.0
01 
0.49 (0.31,0.79) 0.004 
Vaccinated: 
15-20 yrs ago 
0.346 (0.246,0.487) 0.000 0.390 (0.264,0.575) 0.000 
0.43 (0.28,0.67) <0.0
01 
0.34 (0.23,0.50) <0.0
01 
0.41 (0.27,0.63) <0.00
1 
Vaccinated: 
20-25 yrs ago 
0.554 (0.404,0.759) 0.000 0.640 (0.448,0.916) 0.015 
0.75 (0.49,1.14) 0.174 0.56 (0.39,0.80) 0.001 0.69 (0.46,1.02) 0.065 
Vaccinated: 
25-29 yrs ago 
0.565 (0.342,0.932) 0.025 0.772 (0.453,1.315) 0.341 
0.99 (0.53,1.84) 0.97 0.70 (0.40,1.24) 0.225 0.88 (0.48,1.59) 0.66 
 
 
      0Base model is stratified on birth cohort and adjusted for sex 
      1The partially adjusted model  is additionally adjusted for confounding variables area-level deprivation and educational level. 
      2The fully adjusted model is further adjusted for confounding variables area-level deprivation and educational level, lifestyle variables (tobacco smoking, 
alcohol drinking and misuse/abuse of controlled drugs), history of homelessness, history of prison stays, TB infection risk from regular travels abroad. 
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There was strong evidence of a protective effect of the vaccine in each of the 5 year periods 
from 10 to 20 years post-vaccination (table 26).  Results from the model fully adjusted for 
confounders provided evidence of a protective effect 10 to 15 (HRadj 0.49 95% CI 
0.31,0.79:p=0.003) and 15 to 20 years later (HRadj 0.43 95% CI 0.28,0.67:p<0.001) compared 
to after 20 years.  Numbers were too small to assess the effect from 20 to 25 years but 
there was a suggestion of a protective effect . 
These results are based on a complete case analysis (ie based on subjects with no missing 
data). Taking into account missing information may be explored in the future. 
 
Trends in the association between time since BCG vaccination and risk of TB 
Table 27 shows the results from modelling the association between BCG vaccination and log 
hazard of TB as a linear function of time since vaccination, centred at 10 years post -
vaccination. The results are displayed graphically in figure 11. The model suggests a 7% 
increase in the HR with each year post-vaccination, and this was statistically significant 
(95% CI: 0.2% to 12%). We also explored the trend in time using restricted cubic splines 
with 3 knots, respectively at 15, 20 and 25 years post -vaccination. The results were similar 
to those found using the linear model and are not shown here.  
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Table 27 Association between BCG status and risk of TB as a smooth function of time since 
vaccination in the school-age study 
 Partially Adjusted model1  
 
Fully Adjusted  model2   
 
 HR 95% CI p-val HR 95% CI p-val 
Unvaccinated 1 (ref)   1 (ref)   
HR at 10-years 
post-vaccination 
0.310 (0.188,0.511) 0.000 0.374 (0.215,0.652) 0.001 
Multiplying factor 
for each year 
increase in time-
since-vaccination 
1.07 (1.00,1.12) 0.015 1.057 (1.002,1.116) 0.042 
      1The partially adjusted model is stratified on birth cohort and adjusted for confounding variables 
sex, area-level deprivation and educational level. 
      2The fully adjusted model is further adjusted for confounding variables area -level deprivation and 
educational level, lifestyle variables (tobacco smoking, alcohol drinking and misuse/abuse of controlled 
drugs), history of homelessness, history of prison stays, TB infection risk from regular travels abroad  
 
 
 
Figure 10: Results from modelling the time-varying effect of the vaccine as a linear function 
of time (on the log scale) in the school-age study  
The left-hand vertical axis shows the hazard ratio (HR) and the right-hand vertical axis shows the 
vaccine effectiveness (VE), both on the log scale. Results are based on the multivariable adjusted 
model. The dashed lines show the 95% confidence bounds. 
 
The results showed a statistically significant protective effect of the vaccine up to about 23 
years post-vaccination, with a gradual reduction in the protective effect up to that time. The 
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protective effect of the vaccine appears to reduce more steeply after about 20 years post-
vaccination. However, we had only a relatively small number of cases with more than 25 
years post-vaccination and thus have insufficient evidence to assess protection beyond that 
time. 
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Discussion  
These results from our studies of the duration of protection of BCG vaccination indicate that 
protection persists for at least  10 years for infant vaccination and for at least 20 years for 
school-age vaccination. After school-aged BCG vaccination a protective effect of 48% (95% 
CI 17 to 68%) was seen 10 to 15 years after vaccination, and 55% (95% CI 30 to 71%) 15 to 
20 years after vaccination beyond which protection appeared to wane. For infant BCG 
vaccination a protective effect was seen up to 10 years since vaccination (less than 5 years 
after vaccination VE 66%, 95%CI 17% to 86%; 5 to 10 years VE=75%, 95%CI 43 to 89%) 
but with less evidence of an effect 10-15 years later (VE=36%, 95%CI negative to 77%, 
p=0.396).  These results for the infant BCG study were based on subjects for whom vaccine 
records were available in the analysis adjusted for several confounders including birth 
cohort and ethnicity. By adjusting only for ethnicity and birth cohort, slightly more records 
with complete data could be included, giving weak evidence of a 50% VE (95% CI negative 
to 78%, p=0.096) 10 to 15 years after infant BCG vaccination. The higher than expected 
infant BCG vaccine uptake in this high-risk ethnic minority study population and sparsity of 
vaccine record data in the later time periods precluded further assessment.  
Although the findings for infant BCG vaccination in a population at high risk for TB are 
insufficient to assess protective effect beyond 10 years, the evidence is much stronger for a 
moderate protective effect for up to 20 years after school-aged BCG vaccination in the 
native white population. The study findings are consistent with recent findings from 
Norway41 and from Brazil,24 and provides additional evidence to that from the seminal MRC 
trial in which protection of 63% was seen 10 to 15 years after vaccination with wide 
confidence intervals (17 to 84%) with absence of evidence of protection 15 to 20 years after 
vaccination (VE 9% 95% CI negative  to 71).7  
BCG vaccine composition or changes in administration was not considered to be an 
important source of variation over the study period.  Although the liquid Danish BCG was 
replaced in the UK in the 1960s’ by Glaxo freeze dried BCG (Glaxo 1077 vaccine strain 
developed by Glaxo from the Danish Strain and produced in the UK by Evans-Medeva), a 
study comparing both showed non inferiority42, 43.41, 42  From 2002 the UK was only able to 
source BCG from Denmark’s Statens Serum Institute (SSI vaccine also based on the Danish 
Strain 1331) 44 , 45. 43, 44   A recent systematic review of the BCG vaccine trials by our 
research group also suggested protection did not vary in relation to vaccine strain.10  
Multipuncture vaccination use was limited. In our analysis of policy we noted that the 1983 
survey indicated 76% of districts used intradermal BCG vaccination, which increased in the 
1992 survey to 96% of districts.  No data are available comparing protection using 
multipuncture versus intradermal vaccination but sensitisation based on TST testing was 
similar.46 44  
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We had a good response rate in both studies and were successfully able to recruit 
population-based controls to represent both the children born in the UK to populations from 
high TB burden settings and the general population. We were unable to link to vaccine 
records for most of the school-aged BCG subjects despite their willingness to consent to 
such linkage.  Self-reported history of BCG and scar were used instead to measure BCG 
uptake having been found to have good agreement with each other (this agreement was not 
observed, by contrast in those offered BCG in infancy). Although interviewers were not blind 
to case control status or to knowledge of a history of BCG vaccination before scar reading, 
they were specifically trained to identify a BCG scar that included tests based on examining 
volunteers with and  without scars, 10% of interviews selected at random were checked by 
senior staff and standardised reporting was required. The reason for the study, limited 
information on duration of protection, was known from BCG, hence it is unclear if 
interviewers would have been more biased in one direction than the other when reading a 
BCG scar.  There was some confounding due to lower BCG uptake in poorer subjects who 
had a higher risk of TB. We were however able to control for this.   
We were able to evaluate the effectiveness of BCG in BAME population groups despite initial 
concern that this group would be difficult to assess. Consent was obtained to link to vaccine 
records but could only be retrieved for about a half of subjects from either NHS 
administrative areas or patient held records. There was a considerable lack of agreement 
between the different sources of information on infant BCG vaccination. Information on self-
reported BCG uptake in the infant study was also found to be a poor measure of 
vaccination, and scar reading was poorly concordant with vaccine records where available. 
Red book and NIH records also had poor concordance, indicating that BCG vaccination was 
being noted in one record but not necessarily the other. We also noted a higher refusal rate 
for reading a BCG scar in some BAME young adult female cases who were not comfortable 
having their upper arms examined than controls. For both these reasons, we therefore used 
vaccine records where available, despite not having information on uptake for about 40% of 
subjects. Future work may include exploring approaches that could include scar information, 
despite the relatively poor specificity of scar reading noted in this study to reduce the level 
of missing information on vaccination status in the infant vaccination study.  
Addressing the issue of prior infection as the reason for not receiving BCG vaccination   
A theoretical limitation in the school-aged BCG analysis study was the inability to assess 
and exclude from the controls those with prior positive tuberculin skin tests.  Retrospective 
ascertainment of results of TST testing based on recall was clearly not feasible, and there 
was no record to validate participants’ memory recall. Under the routine school vaccination 
programme, prior infection by Mycobacterium tuberculosis (Mtb) or sensitization by 
environmental mycobacterial (EM) was investigated through TST, and such subjects were 
not offered BCG. These subjects are usually not included in studies measuring the effect of 
BCG in the short-term, as there is evidence that the risk of TB is higher in skin test positive 
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subjects during the first few years after infection. Their inclusion would thus act to 
overestimate the protective effect of BCG vaccination. It is also thought that BCG does not 
confer protection in TST positive subjects. However, follow-up data from the British MRC 
BCG trial in adolescents show that—at least in settings with low transmission—the risk of TB 
in participants who were positive to TST declined over time, and was similar to that of 
subjects who were TST negative at baseline by about 10 years after enrolment  (see figure 
12).7, 47 Thus, TST was thought unlikely to play a major role when measuring the 
association between BCG vaccination and TB beyond 10 years after vaccination as in our 
study. Extrapolation of earlier modelling work by one of the authors of the paper48 and this 
document, also suggested the prevalence of tuberculin positivity in the white population in 
general would have been around 4% at the time of screening for vaccination.  
 
 
Figure 11 Comparison of TB rates in BCG vaccinated and unvaccinated by TST status at 
start of follow-up in the British MRC BCG trial in Adolescents  
(Figure based on data from the British MRC trial published in 4th Report Bull WHO 1972)47 
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Conclusions  
In summary, our two observational studies suggest BCG vaccination provides longer lasting 
protection than previously described, particularly for BCG vaccination at school-age where 
we were able to use scar and history as measures of BCG uptake. Protec tion was noted for 
more than two decades after vaccination, but to wane 20 to 25 years after vaccination. The 
findings are consistent with the limited data emerging from other trials and observational 
studies22 as well as a more recent Norwegian historical cohort study of the duration of 
protection of BCG vaccine.41 BCG at school-age may thus have helped in the control of TB 
including the potential for developing multidrug resistant disease as those vaccinated at 
about 13 years of age have moved into adulthood.   
Our current analysis of the infant BCG study, based on just over 50% of the subjects with 
vaccine records and complete information on covariates, was able to confirm the known 
protective effect of infant BCG vaccination against TB for up to 10 years after vaccination 
adjusting for confounders. Numbers were however too sparse after 10 years to provide 
robust evidence of VE for this time period.  Vaccine coverage was higher than expected in 
those with records. Further exploratory analyses to deal with missing records could include 
multiple imputation of missing BCG vaccination status amongst other sensitivity analyses. 
This assessment might inform a review of the incidence levels when countries are 
recommended to suspend BCG vaccination, estimates of cost effectiveness of BCG in 
prevention of tuberculosis, and have implications for testing and scheduling of new vaccines 
against tuberculosis which will need to give better protection than BCG and as durable. We 
also recommend more systematic recording of BCG uptake at the population level by ethnic 
group using the Child Health Information System and linkage to TB events to help provide 
ongoing data to assess protection and duration of protection over the life course.  
 
DRAFT COPY 
NIHR/HTA STUDY 08/17/01 BCG duration of protection against tuberculosis in the UK 
Acknowledgments & Contributions 
69 
 
Acknowledgements  
We would like to thank Reen Polonsky who helped administer the project and support much 
of the logistics at LSHTM. We would particularly like to thank the several members of the 
research team at NatCen who made the fieldwork possible. They include Elizabeth Fuller, 
Alison Moody and Soazig Clifton amongst others. We also thank all the interviewers for their 
careful work and commitment to the project, their supervisors and the operation team 
members as well as all the individuals who allowed us to contact them and help us by taking 
part in the study. Public Health England was a key partner in the research. We thank staff 
there, especially colleagues from the TB Section. We also thank our steering group team for 
their support and advice. The work was funded by NIHR HTA grant no 08/17/01.  A copy of 
the final data will be kept on LSHTM’s data archive (LSHTM Data Compass 
http://datacompass.lshtm.ac.uk/) and will be available after the main results are published 
and at this time will be obtained from the corresponding author via the LSHTM repository.   
 
Contributions  
LR and PM co-designed and co-wrote the proposal. PM provided the managerial lead for the 
project with PND. PM, PND and LR provided academic leadership and other co-applicants 
provided valued academic expertise and advice at key points. RK devised and carried out 
the analyses with assistance from PND and LT. PND, LT and RK carried out data cleaning 
and merging of data across sources. Additional expertise was provided in statistics (JS), 
BCG epidemiology and study design (PF, PS), TB epidemiology, the ETS, BCG vaccine 
records, public health policy and clinical aspects (IA, JW DE and ML), and exploring PPD 
positivity levels in the general population (EV). PND co-wrote a first draft of the report with 
PM and RK.  All authors contributed to the final report.   
 
 
 
 
 
 
 
 
 
DRAFT COPY 
NIHR/HTA STUDY 08/17/01 BCG duration of protection against tuberculosis in the UK 
References 
70 
 
References 
1. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin 
reaction in childhood and adolescence. Am J Epidemiol. 1974 Feb;99(2):131-8 
2. World Health Organization. Global tuberculosis report 2015 20th Edition. 2015. 
3. Crofts JP, Gelb D, Andrews N, Delpech V, Watson JM, Abubakar I. Investigating 
tuberculosis trends in England. Public Health. 2008;122(12):1302-10 
4. European Centre for Disease Prevent ion and Control/WHO Regional Office for Europe. 
Tuberculosis surveillance and monitoring in Europe 2015. 2015. 
5. Public Health England. Tuberculosis in England 2016 (presenting data to end of 
2015) [cited 2016. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/555343/TB
_Annual_Report_2016_GTW2309.pdf. 
6. Kruijshaar ME, Watson JM, Drobniewski F, Anderson C, Brown TJ, Magee JG, et al. 
Increasing antituberculosis drug resistance in the United Kingdom: analysis of national 
surveillance data. British Medical Journal. 2008;336(7655):1231-4 
7. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of 
tuberculosis in adolescence and early adult life. Final report to the Medical Research Council. 
British Medical Journal. 1977;2(6082):293-5 
8. Sutherland I. Effectiveness of BCG vaccination in England and Wales in 1983. 
Tubercle. 1987;68(2):81-92 
9. Anonymous. Trial of BCG vaccines in south India for tuberculosis prevention: first 
report--Tuberculosis Prevention Trial. Bulletin of the World Health Organization. 
1979;57(5):819-27 
10. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by 
BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. 
Clinical infectious diseases  2014 Feb;58(4):470-80 
11. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al.  The 
efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of 
tuberculosis: meta-analyses of the published literature. Pediatrics. 1995;96(1 Pt 1):29-35 
12. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous 
meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993;22(6):1154-8 
13. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated 
BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy 
and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet. 1996 Jul 
6;348(9019):17-24 
14. Barreto ML, Pereira SM, Pilger D, Cruz AA, Cunha SS, Sant'Anna C, et al. Evidence of 
an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: 
second report of the BCG-REVAC cluster-randomised trial. Vaccine. 2011 Jul 
12;29(31):4875-7 
15. Joseph CA, Watson JM, Fern KJ. BCG immunisation in England and Wales: a survey 
of policy and practice in schoolchildren and neonates. BMJ (Clinical research ed ). 
1992;305(6852):495-8 
16. Sutherland I, Springett VH. The effects of the scheme for BCG vaccination of 
schoolchildren in England and Wales and the consequences of discontinuing the scheme at 
various dates. J Epidemiol Community Health. 1989 Mar;43(1):15-24 
17. Anonymous. Criteria for discontinuation of vaccination programmes using Bacille 
Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of 
the International Union Against Tuberculosis and Lung Disease. Tuber Lung Dis. 
1994;75:179-80 
18. Department of Health. PL CMO (2005)3: Changes to the BCG vaccination 
programme2005 15 Apr 2012. Available from: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Professionalletters/C
hiefmedicalofficerletters/DH_4114993. 
19. Department of Health. Immunisation against infectious disease - 'The Green Book' - 
2006 updated edition2007 15 Apr 2012:[391-409 pp.]. Available from: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuida
nce/DH_079917. 
DRAFT COPY 
NIHR/HTA STUDY 08/17/01 BCG duration of protection against tuberculosis in the UK 
References 
71 
 
20. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since 
vaccination? Int J Tuberc Lung Dis. 1998;2(3):200-7 
21. Fine PE, Vynnycky E. The effect of heterologous immunity upon the apparent efficacy 
of (e.g. BCG) vaccines. Vaccine. 1998 Dec;16(20):1923-8 
22. Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, et al. Systematic 
review and meta-analysis of the current evidence on the duration of protection by bacillus 
Calmette-Guerin vaccination against tuberculosis. Health technology assessment. 2013 
Sep;17(37):1-372, v-vi 
23. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER, et 
al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year 
follow-up study. JAMA : the journal of the American Medical Association. 2004 May 
5;291(17):2086-91 
24. Barreto ML, Cunha SS, Pereira SM, Genser B, Hijjar MA, Yury Ichihara M, et al. 
Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int J Tuberc Lung 
Dis. 2005 Oct;9(10):1171-3 
25. Pilger D, Nguipdop-Djomo P, Abubakar I, Elliman D, Rodrigues LC, Watson JM, et al. 
BCG vaccination in England since 2005: a survey of policy and practice. BMJ Open. 
2012;2(5) 
26. Miller CL, Morris J, Pollock TM. PHLS inquiry into current BCG vaccination policy. 
British Medical Journal (Clinical research ed ). 1984;288(6416):564 
27. PHLS. PHLS Enquiry into current BCG vaccination policy, june 1983: Details of 
enquiry reported in letter to BMJ 18.2.84. Report. 1984  
28. Becker E, Boreham R, Chaudhury M, Craig R, Deverill C, Doyle M, et al. Health 
Survey for England 2004 volume 2: Methodology and documentation. Joint Health Survey 
Unit National Centre for Social Research, 2006. 
29. Mindell JS, Tipping S, Pickering K, Hope S, Roth MA, Erens B. The effect of survey 
method on survey participation: analysis of data from the Health Survey for England 2006 
and the Boost Survey for London. BMC Med Res Methodol. 2010;10:83 
30. Office for National Statistics. Population by ethnic group (2001 Census): 
Neighbourhood statistics geographies 2001 [cited 2011]. Available from: 
https://data.gov.uk/dataset/ethnic_group_2001_census. 
31. Office for National Statistics. A beginner's guide to UK geography: Census geography 
2011 [cited 2011]. Available from: http://www.ons.gov.uk/ons/guide-
method/geography/beginner-s-guide/census/index.html. 
32. Office for National Statistics. Population estimates for UK, England and Wales, 
Scotland and Northern Ireland, Mid-2010 2011 [cited 2011]. Available from: 
http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-and-
wales--scotland-and-northern-ireland/mid-2010-population-estimates/index.html. 
33. Office for National Statistics. The English Indices of Deprivation 2010 2011. Available 
from: https://www.gov.uk/government/statistics/english-indices-of-deprivation-2010. 
34. Blake KS, Kellerson RL, Simic A, Inc. E. Measuring overcrowding in housing: a report 
for the US department of housing and urban development, Office of policy development and 
research. 2007. 
35. Office of the Deputy Prime Minister. The impact of overcrowding on health and 
education a review of the evidence and literature. 2004. 
36. Keogh RH, Cox DR. Case-subcohort studies.  Case-control studies: Cambridge 
University Press; 2014. p. 191-211. 
37. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease 
prevention trials. Biometrika. 1986;73(1):1-11 
38. Keogh RH, Mangtani P, Rodrigues L, Djomo PN. Estimating time-varying exposure-
outcome associations using case-control data: logistic and case-cohort analyses. Bmc 
Medical Research Methodology. 2016 Jan 5;16 
39. Health Protection Agency. Tuberculosis in the UK: 2011 report2011 15 Apr 2012. 
Available from: 
http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1317131784267. 
40. Rehm J, Greenfield TK, Walsh G, Xie X, Robson L, Single E. Assessment methods for 
alcohol consumption, prevalence of high risk drinking and harm: a sensitivity analysis. Int J 
Epidemiol. 1999 Apr;28(2):219-24 
DRAFT COPY 
NIHR/HTA STUDY 08/17/01 BCG duration of protection against tuberculosis in the UK 
References 
72 
 
41. Nguipdop-Djomo P, Heldal E, Rodrigues LC, Abubakar I, Mangtani P. Duration of BCG 
protection against tuberculosis and change in efectiveness with time since vaccination in 
Norway: a retrospective population-based cohort study. Lancet Infect Dis 2016. p. 219-26. 
42. Springett VH, Sutherland I. Comparison of the efficacy of liquid and freeze-dried 
strains of B.C.G. vaccine in preventing tuberculosis 12395. British Medical Journal. 
1970;4(728):148-50 
43. Gorak-Stolinska P, Weir RE, Floyd S, Lalor MK, Stenson S, Branson K, et al. 
Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 
1077 BCG vaccine. Vaccine. 2006 Jul 17;24(29-30):5726-33 
44. BCG vaccination by multiple-puncture: fourth report. A report from the Research 
Committee of the British Thoracic and Tuberculosis Association. Tubercle. 1971 
Mar;52(1):19-30 
45. Office TNA. Procurement of Vaccines by the Department of Health2003 12th October 
2016 [30 p.]. Available from: https://www.nao.org.uk/wp-
content/uploads/2003/04/0203625.pdf. 
46. Smith DS. BCG Vaccination by Multiple-Puncture: Third Report. Tubercle. 1965 
Jun;46:111-20 
47. Fourth report to the Medical Research Council by its Tuberculosis Vaccines Clinical 
Trials Committee. BCG and vole bacillus vaccines in the prevention of tuberculosis in 
adolescence and early adult life. Bulletin of the World Health Organization. 1972;1972. 
46:3-85 
48. Vynnycky E, Fine PE. The annual risk of infection with Mycobacterium tuberculos is in 
England and Wales since 1901. Int J Tuberc Lung Dis. 1997 Oct;1(5):389-96 
 
